



李氏大藥廠

Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立之有限公司)

(Stock Code 股份代號:950)

中期 INTERIM 2022
報告 REPORT

* For identification purpose only
僅供識別

INTERIM FINANCIAL STATEMENTS

The directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”) present herewith the unaudited consolidated interim financial results (the “**Interim Results**”) of the Company and its subsidiaries (collectively, the “**Group**”) for the six months ended 30 June 2022, together with the comparative figures for the corresponding period in 2021. The Interim Results are unaudited, but have been reviewed by the Company’s auditor, HLM CPA Limited (the “**Auditor**”) in accordance with Hong Kong Standard on Review Engagements 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Hong Kong Institute of Certified Public Accountants (“**HKICPA**”). The audit committee of the Company has also reviewed with the management and the Auditor the Interim Results before recommending it to the board of Directors (the “**Board**”) for approval.

中期財務報表

李氏大藥廠控股有限公司(「**本公司**」)董事(「**董事**」)謹此呈報本公司及其附屬公司(統稱「**本集團**」)截至二零二二年六月三十日止六個月之未經審核綜合中期財務業績(「**中期業績**」)連同二零二一年同期之比較數字。中期業績未經審核，惟獲本公司核數師恒健會計師行有限公司(「**核數師**」)按照香港會計師公會頒佈之《香港審閱工作準則》第2410號「實體的獨立核數師對中期財務資料的審閱」進行審閱。本公司審核委員會於向董事會推薦中期業績以供批准前，亦已與管理層及核數師審閱中期業績。

BUSINESS REVIEW

Revenue and Profit

During the second-quarter 2022, the implementation of stringent lockdown measures in major cities in China to contain the outbreak of COVID has posed significant business disruption and supply chain challenges. Seeing decent sales growth during the period under review is truly a bliss under the present persistently sagging economy in the region.

First-half 2022 revenue of the Group totalled HK\$649,166,000 (First-half 2021: HK\$584,052,000), an increase of 11.1% compared to the same period last year. Second-quarter 2022 revenue of the Group totalled HK\$324,416,000 (Second-quarter 2021: HK\$300,910,000), an increase of 7.8% compared to the prior-year quarter. Sales growth in the first-half 2022 was primarily driven by the contributions from the newly launched Bredinin™, as well as Treprostinil Injection and Yallaferon® which grew by 48.9% and 4.7%, respectively, and offset lower sales of out-patient drugs such as Ferplex® and surgical drugs such as Livaracine® and Slounase®.

Sales of licensed-in products in the first-half 2022 accounted for 61.2% (First-half 2021: 57.3%) of the Group's revenue while sales of proprietary and generic products in the first-half 2022 contributed 38.8% (First-half 2021: 42.7%) of the Group's revenue.

業務回顧

收益及溢利

於二零二二年第二季度，中國多個主要城市實施嚴格封城措施，以遏止COVID疫情，對業務造成嚴重干擾，並且為供應鏈帶來挑戰。在當前區內經濟持續放緩的情況下，回顧期間的銷售額錄得理想增長，實在難能可貴。

二零二二年上半年，本集團的收益合共為649,166,000港元(二零二一年上半年：584,052,000港元)，較去年同期增加11.1%。本集團二零二二年第二季度的收益合共為324,416,000港元(二零二一年第二季度：300,910,000港元)，較去年同一季度增加7.8%。二零二二年上半年銷售額錄得增長，主要受到新推出的《布累迪寧》™以及曲前列尼爾注射液及《尤靖安》®貢獻的銷售額(分別上升48.9%及4.7%)帶動，抵銷了《菲普利》®等門診藥物以及《立邁青》®及《速樂涓》®等外科藥物的銷售額跌幅。

引進產品於二零二二年上半年的銷售額佔本集團收益61.2%(二零二一年上半年：57.3%)，而專利產品及仿製產品於二零二二年上半年的銷售額則佔本集團收益38.8%(二零二一年上半年：42.7%)。

First-half 2022 gross profit of the Group was HK\$419,478,000 (First-half 2021: HK\$386,546,000), an increase of 8.5% compared to the same period last year. Second-quarter 2022 gross profit of the Group was HK\$203,652,000 (Second-quarter 2021: HK\$194,135,000), an increase of 4.9% compared to the prior-year quarter. Second-quarter 2022 gross profit margin of the Group was 62.8%, decreased by 1.7 percentage points as compared to 64.5% achieved during the prior-year quarter. The Group's overall gross profit margin was 64.6%, decreased by 1.6 percentage points as to 66.2% achieved in the first-half 2021 due to increase in proportion of revenue generated from the sales of licensed-in products.

Research and development (“R&D”) expenses represented new drugs development in major therapeutic areas such as cardiovascular, woman health, paediatrics, rare diseases, dermatology and obstetrics, as well as in oncology under a separate R&D arm within the Group. An aggregate of HK\$206,517,000 has been spent in the first-half 2022 (First-half 2021: HK\$240,043,000), decreased by 14.0% compared to the same period last year and represented 31.8% to the corresponding revenue for the period (First-half 2021: 41.1%). Among which HK\$116,590,000 (First-half 2021: HK\$112,899,000) has been recognised as expenses and HK\$89,927,000 (First-half 2021: HK\$127,144,000) has been capitalised as intangible assets. The Group continues to optimise the resources allocation among prioritised R&D projects and the cost-saving effect thereof has begun to show.

於二零二二年上半年，本集團錄得毛利419,478,000港元(二零二一年上半年：386,546,000港元)，較去年同期增長8.5%。本集團二零二二年第二季度的毛利為203,652,000港元(二零二一年第二季度：194,135,000港元)，較去年同一季度增長4.9%。本集團二零二二年第二季度的毛利率為62.8%，較去年同一季度的64.5%下降1.7個百分點。本集團的整體毛利率為64.6%，較二零二一年上半年的66.2%下降1.6個百分點，是由於引進產品銷售額佔收益的比例上升。

研究及開發(「研發」)費用來自心血管、女性健康、兒科、罕見病、皮膚科及產科等各個主要治療領域的新藥開發，以及本集團內的獨立腫瘤科研發分支。本集團於二零二二年上半年耗資合計206,517,000港元(二零二一年上半年：240,043,000港元)，較去年同期減少14.0%，且相當於相應期間收益31.8%(二零二一年上半年：41.1%)，當中116,590,000港元(二零二一年上半年：112,899,000港元)已確認為費用，而89,927,000港元(二零二一年上半年：127,144,000港元)已資本化作為無形資產。本集團繼續優化各優先研發項目的資源分配，減省成本的效果開始浮現。

The Group's selling and distribution expenses was HK\$176,215,000 in the first-half 2022, representing an increase of HK\$12,097,000 or 7.4% compared to HK\$164,118,000 in the same period last year. Overall, the selling expenses to revenue ratio during the first-half 2022 was 27.1%, slightly decreased by 1.0 percentage point as to 28.1% same period last year. In March 2022, the Group has launched its own flagship online stores on e-commerce platform of Alibaba.com and JD.com to strengthen its brand awareness and expand its sales channels. The Group continues to deploy adequate resources to support the works for strengthening the distribution channels, preparing for the roll-out of new and upcoming products, as well as transforming the brand of selected products of the Group.

Overall, net profit attributable to the owners of the Company in the first-half 2022 was HK\$28,460,000, decreased by 98.7% over the same period in 2021, and was mainly attributable to the net effect of (i) the absence of one-off gain of approximately HK\$2.32 billion attributable to the derecognition of the investment in Zhaoke Ophthalmology Limited as an associate of the Company in April 2021; (ii) the absence of an aggregate one-time loss of approximately HK\$190.1 million attributable to the estimated impairment of intangible assets due to the optimisation of R&D portfolio in the second quarter 2021; and (iii) the absence of one-time loss of approximately HK\$40.2 million attributable to the full impairment for the licensing fee and development cost for a launched oral antihypertensive product previously capitalised, in the second-quarter 2021.

於二零二二年上半年，本集團的銷售及分銷費用為176,215,000港元，較去年同期的164,118,000港元增加12,097,000港元或7.4%。整體而言，二零二二年上半年銷售費用對收益的比率為27.1%，較去年同期的28.1%輕微下降1.0個百分點。於二零二二年三月，本集團已於阿里巴巴及京東商城電子商貿平台推出自家旗艦網店，以加強品牌認知及拓展銷售渠道。本集團亦繼續調撥充足資源支援各項工作，包括強化分銷渠道，為新產品及即將面世的產品上市作準備，以及就本集團的選定產品進行品牌轉型。

整體而言，二零二二年上半年的本公司擁有人應佔純利為28,460,000港元，較二零二一年同期減少98.7%，主要是源於以下各項的淨影響：(i)缺少因於二零二一年四月終止將於兆科眼科有限公司的投資確認為本公司的聯營公司而錄得的一次性收益約23.2億港元；(ii)缺少因二零二一年第二季優化研發組合後產生估計無形資產減值而錄得的一次性虧損總計約190,100,000港元；及(iii)缺少二零二一年第二季度因之前就推出口服降壓藥產品撥充資本的專利費及開發成本全數減值而錄得的一次性虧損約40,200,000港元。

Manufacturing Facilities and Production Capability

Over the years, there have been considerable changes and upgrades in the Group's manufacturing and production capability. During the period under review and up to date, the Group's Hefei site has completed the production capacity expansion and process scale up facility upgrades of Yallaferon®, same line production facility upgrades for new pre-filled syringe injection products before introduction to the market, and the making of registration batch of new product in the form of oral lyophilised powder used as sensitiser in surgery for tumor. In Nansha site, the process scale up equipment installation and commission for the manufacturing of inhaled pharmaceutical aerosols has been completed and will have the process scale up pilot run soon, the production process upgrades for oral dose antihypertension drug is in progress, and the making of three pivotal registration batches of the oral cytotoxic drugs in the special workshop has been completed.

Drug Development

To date, the Group has over 40 projects in its pipeline from early- to late-stage development. The applications made in the prior year for New Drug Application ("NDA") of Adasuve®, and for Abbreviated New Drug Application ("ANDA"), namely Azilsartan, Epinastine Hydrochloride tablet, and Apremilast tablet (阿普米司特片), are under review by the Centre for Drug Evaluation (the "CDE").

製造設施及生產能力

多年來，本集團對其製造及生產能力作出多次大規模變動及升級。於回顧期間及截至目前為止，本集團合肥基地已完成《尤靖安》®產能提升及工藝放大設施升級，預充式注射液新產品上市前共線設施升級改造，以及用作腫瘤手術顯影劑的口服凍乾粉新劑型產品註冊批次生產。南沙基地生產氣溶膠吸入劑的工藝放大設備已完成安裝與調試，將於短期內進行工藝放大試生產工作，用於口服降壓藥產品的生產工藝升級改造工作進行中，而口服細胞毒性藥物已在專用車間完成三批關鍵註冊批次生產。

藥物開發

截至目前為止，本集團管道中有超過40個分別處於早期至後期開發階段的項目。於過往年度提交的Adasuve®新藥上市申請(「新藥申請」)及簡化新藥上市申請(「簡化新藥申請」)(即阿齊沙坦、鹽酸依匹斯汀片及阿普米司特片)正由藥品審評中心(「藥審中心」)評審。

Major Therapeutic Areas

The Group is currently developing several assets in major therapeutic areas, such as cardiovascular, woman health, paediatrics, rare diseases, dermatology and obstetrics, which includes late-stage programs such as (1) Cetraxal® Plus for acute otitis externa (AOE) and acute otitis media with tympanostomy tubes (AOMT) which has just completed its Phase III clinical trial stage and is expected to file application to the CDE in September 2022; and (2) Intrarosa® in the treatment of vulvovaginal atrophy (VVA) which is currently in Phase III clinical trial stage and patient enrolment is in good progress.

Oncology Pipeline

China Oncology Focus Limited (“COF”), a 65% owned subsidiary of the Group, is a clinical development stage company and the Group’s R&D arm focused on oncology with emphasis in immuno-oncology. To date, COF has built a pipeline of 10 oncology assets, including 6 innovative and 4 generics, through internal development and in-licensing, and is currently developing several assets, including (1) Socazolimab (an anti-PD-L1 antibody) in recurrent or metastatic cervical cancer in new drug application stage in China; (2) Socazolimab in osteosarcoma in Phase III clinical trial; (3) Socazolimab combined with chemotherapy in small cell lung cancer in Phase III clinical trial and has completed the patient enrollment in May 2022; (4) Zotiraciclib, an oral multi-kinase inhibitor in Phase I clinical trial for glioblastoma; (5) Gimতেcan, a topoisomerase I inhibitor in Phase II clinical trial for ovarian cancer and in Phase Ib/II clinical trial for small cell lung cancer and a Phase I clinical trial for pancreatic cancer in China; and (6) Socazolimab combined with Pexa-vec (oncolytic virus) which is in Phase Ib clinical trial for melanoma.

主要治療領域

本集團現正開發心血管、女性健康、兒科、罕見病、皮膚科及產科等主要治療領域的多項資產，包括處於後期開發階段的計劃，例如(1) Cetraxal® Plus，治療急性外耳道炎及伴有鼓膜置管的急性中耳炎，剛完成第III期臨床試驗階段，預計於二零二二年九月向藥審中心提交申請；及(2) Intrarosa®，用於治療外陰陰道萎縮，目前處於第III期臨床試驗階段，患者入組進度良好。

腫瘤管道

由本集團擁有65%權益的附屬公司中國腫瘤醫療有限公司(「COF」)為本集團在腫瘤科方面的研發分支，並為臨床開發階段公司，專研免疫腫瘤療法領域。截至目前為止，COF已通過內部開發及從外引進的方式建立涵蓋10項腫瘤資產的管道，包括6項創新藥及4項仿製藥，現正開發多項資產，包括(1) Socazolimab(抗PD-L1抗體)，於中國處於復發性或轉移性宮頸癌新藥申請階段；(2) Socazolimab骨肉瘤第III期臨床試驗；(3) Socazolimab結合化療的小細胞肺癌第III期臨床試驗，並已於二零二二年五月完成患者入組；(4) Zotiraciclib，一種口服多激酶抑制劑，現正進行膠質母細胞瘤第I期臨床試驗；(5) 吉馬替康，一種拓撲異構酶I抑制劑，現正於中國進行卵巢癌第II期臨床試驗、小細胞肺癌第Ib/II期臨床試驗及胰臟癌第I期臨床試驗；及(6) Socazolimab結合Pexa-vec(溶瘤病毒)，現正進行黑色素瘤第Ib期臨床試驗。

During the period under review and up to date, the Group obtained 6 ANDA and IDL approvals from NMPA.

Zingo®

On 1 March 2022, the Drug Registration Certificate for Zingo® (Lidocaine Hydrochloride Powder Intradermal Injection System) has been obtained from the NMPA. Zingo® is an amide local anesthetic indicated for use on intact skin to provide local analgesia prior to venipuncture or peripheral intravenous cannulation in children 3–18 years of age and to provide topical local analgesia prior to venipuncture in adults. The rapid onset of analgesia in 1–3 minutes provides care givers and patients the opportunity for a pain-free and needle-free access procedure.

INOmax®

On 8 March 2022, the Drug Registration Certificate for INOmax® (nitric oxide gas for inhalation) has been obtained from the NMPA. INOmax® is a therapy for the treatment of hypoxic respiratory failure (“HRF”) associated with pulmonary hypertension (“PPHN”) in term and near-term infants greater than 34 weeks gestational age. PPHN is a serious condition in which blood vessels in the lungs constrict, making it difficult to oxygenate blood, often resulting in HRF. INOmax® is a vasodilator which selectively relaxes pulmonary blood vessels and, in conjunction with ventilatory support and other appropriate agents, improves oxygenation in this fragile newborn population.

High Concentration Treprostinil Injection

On 9 March 2022, the Drug Registration Certificate for High Concentration Treprostinil Injection (specification: 20ml:50mg) developed and manufactured by Zhaoke Pharmaceutical (Hefei) Co. Limited, a wholly-owned subsidiary of the Company, has been obtained from the NMPA.

於回顧期間及截至目前為止，本集團已取得國家藥監局發出6項簡化新藥申請及進口藥品註冊證批准。

Zingo®

於二零二二年三月一日，Zingo®(鹽酸利多卡因粉末皮內注射給藥系統)取得國家藥監局的藥品註冊許可證。Zingo®為用於皮膚表層的醯胺局部麻醉劑，用於3至18歲兒童靜脈穿刺或周邊靜脈插管前局部鎮痛，以及成人靜脈穿刺前外用局部鎮痛。Zingo®注射後1–3分鐘即見鎮痛效果，為護理人員及患者提供無痛、無針的注射。

INOmax®

於二零二二年三月八日，INOmax®(一氧化氮吸入性氣體)取得國家藥監局的藥品註冊許可證。INOmax®是一種用於治療患有低氧性呼吸衰竭伴隨肺動脈高壓的足月兒及34週以上早產兒的療法。肺動脈高壓是一種肺血管收縮導致血液難以供氧的嚴重疾病，經常導致低氧性呼吸衰竭。INOmax®是一種血管擴張劑，可選擇性地放鬆肺血管，並通過配合換氣裝置及其他適當藥物，改善脆弱新生兒群體的氧合。

高濃度曲前列尼爾注射液

於二零二二年三月九日，本公司全資附屬公司兆科藥業(合肥)有限公司開發及製造的高濃度曲前列尼爾注射液(規格：20毫升：50毫克)取得國家藥監局的藥品註冊許可證。

Natulan®

On 21 April 2022, the Drug Registration Certificate for Natulan® (Procarbazine Hydrochloride Capsules) has been obtained from the NMPA. Natulan® has been approved for combining with chemotherapy to treat Hodgkin's lymphoma (HL) in adult.

Teglutik®

On 31 May 2022, the Drug Registration Certificate for Teglutik® (Riluzole Oral Suspension) has been obtained from the NMPA. Teglutik® has been approved to prolong life or delay the institution of mechanical ventilation in patients with amyotrophic lateral sclerosis (ALS).

Nadroparin Calcium Injection

On 31 May 2022, the Drug Registration Certificate for Nadroparin Calcium Injection has been obtained from the NMPA.

Business Partnership

In-licensing approach is the Group's preferred mode of business development strategy. Nevertheless, the Group has remained selective in entering new in-licensing deals. On 18 July 2022, the Group has entered into a license agreement with Unicycive Therapeutics, Inc., a NASDAQ-listed company, pursuant to which the Group has been granted exclusive rights to develop, market and commercialise Renazorb® (lanthanum dioxycarbonate) in Mainland China, Hong Kong, and certain other Asian markets. Renazorb® is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients.

Natulan®

於二零二二年四月二十一日，Natulan®（鹽酸丙卡巴胍膠囊）取得國家藥監局的藥品註冊許可證。Natulan®獲認可用於結合化療醫治成人霍奇金淋巴瘤。

Teglutik®

於二零二二年五月三十一日，Teglutik®（利魯唑口服混懸液）已取得國家藥監局的藥品註冊許可證。Teglutik®獲認可用於延長肌萎縮性脊髓側索硬化症患者的生命或延長其發展至需要機械通氣支持的時間。

那曲肝素鈣注射液

於二零二二年五月三十一日，那曲肝素鈣注射液已取得國家藥監局的藥品註冊許可證。

業務夥伴

引進策略為本集團業務發展策略的首選模式。然而，本集團在訂立新的引進交易時，仍然堅持精挑細選。於二零二二年七月十八日，本集團與納斯達克上市公司Unicycive Therapeutics, Inc.訂立特許協議，據此，本集團獲授於中國內地、香港及若干其他亞洲市場開發、營銷及商品化生產Renazorb®（二氧碳酸鏷）的獨家權利。Renazorb®是創新磷酸鹽結合劑，開發目的為治療慢性腎病患者的高磷血症。

PROSPECTS

Looking ahead to the second-half 2022, the market environment remains challenging amid uncertainties on various external factors such as COVID pandemic, geopolitical tensions and rising inflation, and the Group will closely monitor the impact thereof and on the other hand, the Group will keep expenditure within the limits of revenue.

In addition, reform measures within the pharmaceutical industry in China, aim at increasing access to drugs and making drugs affordable, has forced the Group to consider the driving force of its future development. Given the current volume-based procurement (“VBP”) program in China, it is expected that the competitive edge of imported originator products will be gradually diminishing when the localised affordable generics become more widely available. Recently, the Group’s Fondaparinux Sodium has been successfully entered into the VBP program, and it is expected that more products, such as low molecular weight heparin, will have the chance to enter into the upcoming VBP programs and to provide additional revenue for the Group. Accordingly, the Group contemplates that the best solution for Carnitene[®], a potential target in the upcoming VBP program and its licensing agreement expiring in the second-half 2022, will be to develop the domestic generic version to pave the way for the Group’s long-term prosperity, and the Group 6 newly approved products during the period under review and up to date, and 2 more NDA approvals expected to be received in the year ending 2022, shall also provide new revenue streams for the Group during the transformation.

Furthermore, the Group has implemented a series of measures to adapt to the “new normal” and to emphasis efficiency at every step of the value chain, particularly in key areas such as sales and R&D, after taking the present conditions into consideration, and the effect has begun to show.

展望

展望二零二二年下半年，在COVID疫情、地緣政治緊張及通脹飆升等一連串外部因素影響下，市場環境仍然不明朗且充滿挑戰，本集團將密切監察有關影響，同時量入為出。

此外，為使藥物更為大眾化和可負擔，中國執行若干藥業改革措施，促使本集團思考未來發展的增長動力。鑑於中國目前實行藥品集中帶量採購（「藥品集採」）計劃，預期原廠進口產品的競爭優勢將逐步減退，而價格合理的國產仿製藥則會更為普及。近期，本集團的磺達肝癔鈉成功進入藥品集採計劃，預期更多產品（如低分子量肝素）將有機會加入未來的藥品集採計劃，為本集團帶來額外收益。因此，本集團認為，鑑於《可益能》[®]有可能成為未來藥品集採計劃的目標，且其許可協議將於二零二二年下半年屆滿，故最佳辦法將為開發國產仿製版本，才能為本集團長遠蓬勃發展奠定基礎；同時，本集團於回顧期間及截至目前為止有6項新產品獲批准，另有2項預計將於二零二二年度取得新藥申請批准，亦將有望於轉型期間成為本集團新的收益來源。

再者，於考慮到當前環境後，本集團已實施一連串措施適應「新常態」，價值鏈中的每一個環節（尤其是銷售及研發等關鍵流程）均強調效率，成效亦已開始展現。

The Group firmly believes that all these works to be done will endeavour to strengthen its competitiveness and create more value to reward its shareholders, staff and customers for their support.

FINANCIAL REVIEW

Gross Profit Margin

The Group recorded a gross profit of HK\$419,478,000 for the first-half 2022, increased by 8.5% as compared to the corresponding period of HK\$386,546,000. Gross profit margin was 64.6% during the period under review, decreased by 1.6 percentage points as compared to 66.2% recorded in the corresponding period last year, which was mainly attributable to the increase in proportion of revenue generated from the sales of licensed-in products.

Other Gains and Losses, Net

For the first-half 2022, the Group recorded a HK\$5,227,000 other losses (net) as compared to a HK\$2,093,266,000 other gains (net) in the first-half 2021. The turnaround was mainly attributable to the net effect of (i) the absence of one-off gain of approximately HK\$2.32 billion attributable to the derecognition of the investment in Zhaoke Ophthalmology Limited as an associate of the Company in April 2021; (ii) the absence of an aggregate one-time loss of approximately HK\$190.1 million attributable to the estimated impairment of intangible assets due to the optimisation of R&D portfolio in the second quarter 2021; and (iii) the absence of one-time loss of approximately HK\$40.2 million attributable to the full impairment for the licensing fee and development cost for a launched oral antihypertensive product previously capitalised, in the second-quarter 2021.

本集團深信，上述各項工作將可增強其競爭力，最終為鼎力支持本集團的股東、員工及客戶創造更高價值。

財務回顧

毛利率

於二零二二年上半年，本集團錄得毛利419,478,000港元，較去年同期的386,546,000港元增加8.5%。回顧期間的毛利率為64.6%，較去年同期錄得的66.2%下跌1.6個百分點，主要源於引進產品銷售額佔收益的比例上升。

其他收益及虧損淨額

本集團於二零二二年上半年錄得其他虧損(淨額)5,227,000港元，二零二一年上半年則錄得其他收益(淨額)2,093,266,000港元。由盈轉虧主要源於以下各項的淨影響：(i)缺少因於二零二一年四月終止將於兆科眼科有限公司的投資確認為本公司的聯營公司而錄得的一次性收益約23.2億港元；(ii)缺少因二零二一年第二季優化研發組合後產生估計無形資產減值而錄得的一次性虧損總計約190,100,000港元；及(iii)缺少二零二一年第二季度因之前就推出口服降壓藥產品撥充資本的專利費及開發成本全數減值而錄得的一次性虧損約40,200,000港元。

Selling and Distribution Expenses

With continuous resources being deployed in strengthening the distribution channel, preparing for the roll-out of new and upcoming products, and transforming the brand of selected products of the Group, total selling and distribution expenses for the first half 2022 was HK\$176,215,000, representing an increase of HK\$12,097,000, or 7.4%, compared with the corresponding period of last year of HK\$164,118,000, and accounted for 27.1% of the Group's revenue, decreased by 1.0 percentage point from 28.1% in the same period last year.

Research and Development Expenses

Research and development expenses for the first half 2022 was HK\$116,590,000, increased by 3.3% as compared with HK\$112,899,000 recorded in same period last year, representing 18.0% of the Group's revenue whereas it was 19.3% of the Group's revenue in first half 2021. The Group continues to optimise the resources allocation among prioritised projects.

Administrative Expenses

Administrative expenses for the six months ended 30 June 2022 was HK\$111,075,000, decreased by 10.6% as compared with HK\$124,201,000 in the same period last year. The Group continues to optimise the resources allocation in operations.

銷售及分銷費用

隨着本集團繼續調撥資源強化分銷渠道、為新產品及即將面世的產品上市作準備，以及就本集團的選定產品進行品牌轉型，二零二二年上半年銷售及分銷費用總額達176,215,000港元，較去年同期的164,118,000港元增加12,097,000港元或7.4%，佔本集團收益27.1%，較去年同期的28.1%下跌1.0個百分點。

研究及開發費用

二零二二年上半年的研究及開發費用為116,590,000港元，較去年同期的112,899,000港元增加3.3%，佔本集團收益18.0%，於二零二一年上半年則佔19.3%。本集團繼續優化各優先研發項目的資源分配。

行政費用

截至二零二二年六月三十日止六個月的行政費用為111,075,000港元，較去年同期的124,201,000港元減少10.6%。本集團繼續優化各項營運的資源分配。

Other Payables and Accruals

Total other payables and accruals balance as at 30 June 2022 was HK\$676,710,000 (31 December 2021: HK\$724,670,000). Other payables and accruals mainly included prepayments from customers, amounts payable in respect of sales guarantee deposit and license fee. HK\$47,960,000 decrease in the first-half 2022 was primarily attributable to settlement of accruals.

Liquidity and Financial Resources

The Group's principal sources of working capital in the current period included cash flow from operating activities.

As at 30 June 2022, the Group's current ratio (current assets divided by current liabilities) was 1.04 (31 December 2021: 1.04). As at 30 June 2022, the Group had net cash position of HK\$147,543,000 (31 December 2021: net cash of HK\$30,899,000) which represented by below:

		30 June 2022	31 December 2021
		二零二二年 六月三十日	二零二一年 十二月三十一日
		HK\$'000	HK\$'000
		千港元	千港元
Net cash position	現金淨額狀況		
Cash and bank balances	現金及銀行結餘	368,047	277,529
Less: Bank borrowings	減：銀行借款	(220,504)	(246,630)
		147,543	30,899

The calculation of Group's gearing ratio based on the net borrowings (after deducting cash and cash equivalents) to equity attributable to the owners of the Company was Nil as at 30 June 2022 (31 December 2021: Nil).

其他應付款項及應計費用

於二零二二年六月三十日，其他應付款項及應計費用結餘總額為676,710,000港元(二零二一年十二月三十一日：724,670,000港元)。其他應付款項及應計費用主要包括來自客戶的預付款項、有關銷售保證按金的應付款項及專利費。二零二二年上半年錄得跌幅47,960,000港元主要因支付應計費用所致。

流動資金及財務資源

本集團於本期間的主要營運資金來源包括來自經營業務的現金流量。

於二零二二年六月三十日，本集團的流動比率(流動資產除以流動負債)為1.04(二零二一年十二月三十一日：1.04)。於二零二二年六月三十日，本集團的現金淨額狀況為147,543,000港元(二零二一年十二月三十一日：現金淨額30,899,000港元)，其如下所示：

	30 June 2022	31 December 2021
	二零二二年 六月三十日	二零二一年 十二月三十一日
	HK\$'000	HK\$'000
	千港元	千港元
Cash and bank balances	368,047	277,529
Less: Bank borrowings	(220,504)	(246,630)
	147,543	30,899

本集團基於借款淨額(扣除現金及現金等值後)對本公司擁有人應佔權益計算的資產負債率於二零二二年六月三十日為零(二零二一年十二月三十一日：零)。

Taking into consideration the existing financial resources available to the Group, it is believed that the Group should have adequate financial resources to meet its operation and development requirements in the future.

Foreign Exchange Exposure

Currently, the Group earns revenue and incurs costs in Renminbi, Hong Kong dollars, European Union euro, Japanese Yen, New Taiwan dollars and United States dollars. The Directors believe that the Group does not have foreign exchange problems in meeting its foreign exchange requirements. The Group will continue to monitor closely its foreign currency exposure and to consider hedging significant foreign currency exposure when necessary.

Pledge of Assets

The Group has no pledge of assets of the Group as at 30 June 2022.

Employee Information

As at 30 June 2022, the Group had 1,182 (31 December 2021: 1,319) employees working in Hong Kong, Mainland China and Taiwan.

Total employee remuneration, including directors' remuneration, retirement benefits provision and mandatory provident fund contributions, for the period under review amounted to approximately HK\$200.9 million (six months ended 30 June 2021: HK\$180.3 million). The Group's emolument policies are formulated on the performance of individual employees and on the basis of the trends of salaries in various regions, which will be reviewed regularly every year. Apart from provident fund scheme, retirement benefits scheme and medical insurance, employees share options are also awarded to employees according to the assessment of individual performance.

經考慮可供本集團使用的現有財務資源後，相信本集團擁有充裕財務資源以應付日後在營運及發展方面所需。

外匯風險

目前，本集團所賺取的收益及所產生的成本以人民幣、港元、歐元、日圓、新台幣及美元計值。董事相信本集團在應付外匯需要時不會面對外匯問題。本集團將繼續密切監察外幣風險，並考慮於有需要時對沖重大外幣風險。

資產抵押

本集團於二零二二年六月三十日並無已抵押之資產。

僱員資料

於二零二二年六月三十日，本集團於香港、中國內地及台灣工作的僱員人數為1,182人(二零二一年十二月三十一日：1,319人)。

回顧期的總僱員薪酬(包括董事薪酬、退休福利撥備及強制性公積金供款)約為200,900,000港元(截至二零二一年六月三十日止六個月：180,300,000港元)。本集團的酬金政策乃按個別僱員的表現及基於不同地區的薪金趨勢而定，並會每年定期檢討。除強制性公積金計劃、退休福利計劃及醫療保險外，本集團亦會按照個別表現評估向僱員授出僱員購股權。

SHARE OPTION SCHEME

Pursuant to a written resolution passed by all shareholders of the Company on 26 June 2002, the Company adopted a share options scheme (the "2002 Share Option Scheme"). At the annual general meeting of the Company held on 10 May 2012, a new share option scheme of the Company (the "2012 Share Option Scheme") was adopted upon expiry of the 2002 Share Option Scheme. At the annual general meeting of the Company held on 19 May 2022, a new share option scheme of the Company (the "2022 Share Option Scheme") was adopted upon expiry of the 2012 Share Option Scheme.

Details of the Company's share option schemes are summarised as follow:

購股權計劃

根據本公司全體股東於二零零二年六月二十六日通過的書面決議案，本公司採納一項購股權計劃（「二零零二年購股權計劃」）。於二零一二年五月十日舉行的本公司股東週年大會上，本公司於二零零二年購股權計劃屆滿時採納一項新購股權計劃（「二零一二年購股權計劃」）。於二零二二年五月十九日舉行的本公司股東週年大會上，本公司於二零一二年購股權計劃屆滿時採納一項新購股權計劃（「二零二二年購股權計劃」）。

本公司的購股權計劃詳情概述如下：

Date of grant	Vesting period	No. of options during the period				At Exercise		Exercise price per share
		At 01.01.2022	Grant	Exercised	Lapsed	30.06.2022	period	
授出日期	歸屬期	於二零二二年一月一日	已授出	已行使	已失效	於二零二二年六月三十日	行使期	每股行使價 HK\$ 港元
Category I: Directors								
第一類：董事								
30.12.2013	30.12.2013 to 29.06.2014	338,000	-	-	-	338,000	30.06.2014 to 29.12.2023	7.300
二零一三年十二月三十日	二零一三年十二月三十日至二零一四年六月二十九日						二零一四年六月三十日至二零二三年十二月二十九日	
	30.12.2013 to 29.03.2015	538,000	-	-	-	538,000	30.03.2015 to 29.12.2023	7.300
	二零一三年十二月三十日至二零一五年三月二十九日						二零一五年三月三十日至二零二三年十二月二十九日	
31.03.2015	31.03.2015 to 29.09.2015	669,000	-	-	-	669,000	30.09.2015 to 30.03.2025	11.200
二零一五年三月三十一日	二零一五年三月三十一日至二零一五年九月二十九日						二零一五年九月三十日至二零二五年三月三十日	
	31.03.2015 to 29.06.2016	669,000	-	-	-	669,000	30.06.2016 to 30.03.2025	11.200
	二零一五年三月三十一日至二零一六年六月二十九日						二零一六年六月三十日至二零二五年三月三十日	

Date of grant	Vesting period	No. of options during the period 期內購股權數目				At Exercise		Exercise price per share 每股行使價 HK\$ 港元
		At 01.01.2022 於二零二二年一月一日	Grant 已授出	Exercised 已行使	Lapsed 已失效	30.06.2022 period 於二零二二年六月三十日	period 行使期	
31.03.2016	31.03.2016 to 29.09.2016	880,500	-	-	-	880,500	30.09.2016 to 30.03.2026	5.754
二零一六年三月三十一日	二零一六年三月三十一日至二零一六年九月二十九日	880,500	-	-	-	880,500	二零一六年九月三十日至二零二六年三月三十一日	5.754
	31.03.2016 to 29.06.2017						30.06.2017 to 30.03.2026	
	二零一六年三月三十一日至二零一七年六月二十九日						二零一七年六月三十日至二零二六年三月三十一日	
13.04.2017	13.04.2017 to 12.10.2017	885,000	-	-	-	885,000	13.10.2017 to 12.04.2027	7.548
二零一七年四月十三日	二零一七年四月十三日至二零一七年十月十二日						二零一七年十月十三日至二零二七年四月十二日	
	13.04.2017 to 12.07.2018	885,000	-	-	-	885,000	13.07.2018 to 12.04.2027	7.548
	二零一七年四月十三日至二零一八年七月十二日						二零一八年七月十三日至二零二七年四月十二日	
13.04.2018	13.04.2018 to 12.10.2018	684,000	-	-	-	684,000	13.10.2018 to 12.04.2028	11.216
二零一八年四月十三日	二零一八年四月十三日至二零一八年十月十二日						二零一八年十月十三日至二零二八年四月十二日	
	13.04.2018 to 12.07.2019	684,000	-	-	-	684,000	13.07.2019 to 12.04.2028	11.216
	二零一八年四月十三日至二零一九年七月十二日						二零一九年七月十三日至二零二八年四月十二日	
15.04.2019	15.04.2019 to 14.10.2019	888,000	-	-	-	888,000	15.10.2019 to 14.04.2029	7.324
二零一九年四月十五日	二零一九年四月十五日至二零一九年十月十四日						二零一九年十月十五日至二零二九年四月十四日	
	15.04.2019 to 14.07.2020	888,000	-	-	-	888,000	15.07.2020 to 14.04.2029	7.324
	二零一九年四月十五日至二零二零年七月十四日						二零二零年七月十五日至二零二九年四月十四日	

Date of grant	Vesting period	No. of options during the period 期內購股權數目				At Exercise period		Exercise price per share 每股行使價 HK\$ 港元
		At 01.01.2022 於二零二二年一月一日	Grant 已授出	Exercised 已行使	Lapsed 已失效	30.06.2022 於二零二二年六月三十日	Exercise period 行使期	
15.04.2020	15.04.2020 to 14.10.2020	882,000	-	-	-	882,000	15.10.2020 to 14.04.2030	3.648
二零二零年 四月十五日	二零二零年四月十五日至 二零二零年十月十四日	882,000	-	-	-	882,000	二零二零年十月十五日至 二零二零年四月十四日	3.648
21.04.2021	15.04.2020 to 14.07.2021	882,000	-	-	-	882,000	15.07.2021 to 14.04.2030	5.806
二零二一年 四月二十一日	二零二零年四月十五日至 二零二一年七月十四日	882,000	-	-	-	882,000	二零二一年七月十五日至 二零二零年四月十四日	5.806
21.04.2021	21.04.2021 to 20.10.2021	882,000	-	-	-	882,000	21.10.2021 to 20.04.2031	5.806
二零二一年 四月二十一日	二零二一年四月二十一日至 二零二一年十月二十日	882,000	-	-	-	882,000	二零二一年十月二十一日至 二零三一年四月二十日	5.806
25.04.2022	21.04.2021 to 20.07.2022	882,000	-	-	-	882,000	21.07.2022 to 20.04.2031	2.076
二零二二年 四月二十五日	二零二一年四月二十一日至 二零二二年七月二十日	-	588,000	-	-	588,000	二零二二年七月二十一日至 二零三一年四月二十日	2.076
25.04.2022	25.04.2022 to 24.10.2022	-	588,000	-	-	588,000	25.10.2022 to 24.04.2032	2.076
二零二二年 四月二十五日	二零二二年四月二十五日至 二零二二年十月二十四日	-	588,000	-	-	588,000	二零二二年十月二十五日至 二零三二年四月二十四日	2.076
	25.04.2022 to 24.07.2023	-	588,000	-	-	588,000	25.07.2023 to 24.04.2032	2.076
	二零二二年四月二十五日至 二零二三年七月二十四日						二零二三年七月二十五日至 二零三二年四月二十四日	

Date of grant	Vesting period	No. of options during the period 期內購股權數目				At Exercise period		Exercise price per share 每股行使價 HK\$ 港元
		At 01.01.2022 於二零二二年一月一日	Grant 已授出	Exercised 已行使	Lapsed 已失效	30.06.2022 於二零二二年六月三十日	Exercise period 行使期	
Category II: Employees								
第二類：僱員								
08.10.2012	08.10.2012 to 07.10.2013	200,000	-	-	-	200,000	08.10.2013 to 07.10.2022	4.996
二零一二年十月八日	二零一二年十月八日至 二零一三年十月七日						二零一三年十月八日至 二零二二年十月七日	
	08.10.2012 to 07.10.2014	635,000	-	-	-	635,000	08.10.2014 to 07.10.2022	4.996
	二零一二年十月八日至 二零一四年十月七日						二零一四年十月八日至 二零二二年十月七日	
	08.10.2012 to 07.10.2015	1,675,000	-	-	-	1,675,000	08.10.2015 to 07.10.2022	4.996
	二零一二年十月八日至 二零一五年十月七日						二零一五年十月八日至 二零二二年十月七日	
05.04.2013	05.04.2013 to 04.10.2013	150,000	-	-	-	150,000	05.10.2013 to 04.04.2023	5.620
二零一三年四月五日	二零一三年四月五日至 二零一三年十月四日						二零一三年十月五日至 二零二三年四月四日	
	05.04.2013 to 04.07.2014	150,000	-	-	-	150,000	05.07.2014 to 04.04.2023	5.620
	二零一三年四月五日至 二零一四年七月四日						二零一四年七月五日至 二零二三年四月四日	
30.12.2013	30.12.2013 to 29.12.2014	604,000	-	-	-	604,000	30.12.2014 to 29.12.2023	7.300
二零一三年十二月三十日	二零一三年十二月三十日至 二零一四年十二月二十九日						二零一四年十二月三十日至 二零二三年十二月二十九日	
	30.12.2013 to 29.12.2015	620,000	-	-	-	620,000	30.12.2015 to 29.12.2023	7.300
	二零一三年十二月三十日至 二零一五年十二月二十九日						二零一五年十二月三十日至 二零二三年十二月二十九日	
	30.12.2013 to 29.12.2016	650,000	-	-	-	650,000	30.12.2016 to 29.12.2023	7.300
	二零一三年十二月三十日至 二零一六年十二月二十九日						二零一六年十二月三十日至 二零二三年十二月二十九日	

Date of grant	Vesting period	No. of options during the period 期內購股權數目				At Exercise period 於二零二二年 六月三十日	Exercise price per share 每股行使價 HK\$ 港元	
		At 01.01.2022 於二零二二年 一月一日	Grant 已授出	Exercised 已行使	Lapsed 已失效			
07.10.2014	07.10.2014 to 29.06.2015	300,000	-	-	-	300,000	30.06.2015 to 06.10.2024	10.340
二零一四年 十月七日	二零一四年十月七日至 二零一五年六月二十九日						二零一五年六月三十日至 二零二四年十月六日	
	07.10.2014 to 02.10.2015	250,000	-	-	-	250,000	03.10.2015 to 06.10.2024	10.340
	二零一四年十月七日至 二零一五年十月二日						二零一五年十月三日至 二零二四年十月六日	
	07.10.2014 to 29.06.2016	300,000	-	-	-	300,000	30.06.2016 to 06.10.2024	10.340
	二零一四年十月七日至 二零一六年六月二十九日						二零一六年六月三十日至 二零二四年十月六日	
	07.10.2014 to 02.10.2016	250,000	-	-	-	250,000	03.10.2016 to 06.10.2024	10.340
	二零一四年十月七日至 二零一六年十月二日						二零一六年十月三日至 二零二四年十月六日	
	07.10.2014 to 02.10.2017	250,000	-	-	-	250,000	03.10.2017 to 06.10.2024	10.340
	二零一四年十月七日至 二零一七年十月二日						二零一七年十月三日至 二零二四年十月六日	
03.10.2017	03.10.2017 to 02.10.2018	250,000	-	-	-	250,000	03.10.2018 to 02.10.2027	6.190
二零一七年 十月三日	二零一七年十月三日至 二零一八年十月二日						二零一八年十月三日至 二零二七年十月二日	
	03.10.2017 to 02.10.2019	250,000	-	-	-	250,000	03.10.2019 to 02.10.2027	6.190
	二零一七年十月三日至 二零一九年十月二日						二零一九年十月三日至 二零二七年十月二日	
	03.10.2017 to 02.10.2020	250,000	-	-	-	250,000	03.10.2020 to 02.10.2027	6.190
	二零一七年十月三日至 二零二零年十月二日						二零二零年十月三日至 二零二七年十月二日	
	03.10.2017 to 02.10.2021	500,000	-	-	-	500,000	03.10.2021 to 02.10.2027	6.190
	二零一七年十月三日至 二零二一年十月二日						二零二一年十月三日至 二零二七年十月二日	

Date of grant	Vesting period	No. of options during the period 期內購股權數目				At Exercise period		Exercise price per share 每股行使價 HK\$ 港元
		At 01.01.2022 於二零二二年一月一日	Grant 已授出	Exercised 已行使	Lapsed 已失效	30.06.2022 於二零二二年六月三十日	Exercise period 行使期	
15.04.2020	15.04.2020 to 14.10.2021	3,525,000	-	-	-	3,525,000	15.10.2021 to 14.04.2030	3.648
二零二零年四月十五日	二零二零年四月十五日至二零二一年十月十四日	3,525,000	-	-	-	3,525,000	二零二一年十月十五日至二零二零年四月十四日	3.648
23.10.2020	23.10.2020 to 22.10.2021	500,000	-	-	-	500,000	15.04.2023 to 14.04.2030	5.310
二零二零年十月二十三日	二零二零年四月十五日至二零二三年四月十四日	500,000	-	-	-	500,000	二零二三年四月十五日至二零二零年四月十四日	5.310
	23.10.2020 to 22.10.2022	500,000	-	-	-	500,000	23.10.2021 to 22.10.2030	5.310
	二零二零年十月二十三日	500,000	-	-	-	500,000	二零二一年十月二十三日至二零二零年十月二十二日	5.310
	23.10.2020 to 22.10.2023	500,000	-	-	-	500,000	23.10.2022 to 22.10.2030	5.310
	二零二零年十月二十三日	500,000	-	-	-	500,000	二零二二年十月二十三日至二零二零年十月二十二日	5.310
	23.10.2020 to 22.10.2024	500,000	-	-	-	500,000	23.10.2023 to 22.10.2030	5.310
	二零二零年十月二十三日	500,000	-	-	-	500,000	二零二三年十月二十三日至二零二零年十月二十二日	5.310
	二零二四年十月二十二日	500,000	-	-	-	500,000	23.10.2024 to 22.10.2030	5.310
	二零二四年十月二十三日至二零二零年十月二十二日	500,000	-	-	-	500,000	二零二四年十月二十三日至二零二零年十月二十二日	5.310
Total 總計		28,751,000	1,176,000	-	-	29,927,000		
Exercisable at the end of the period 於期末可行使						22,844,000		
Weighted average exercise price 加權平均行使價		HK\$6.116 6.116港元	HK\$2.076 2.076港元	-	-	HK\$5.957 5.957港元		

On 25 April 2022, the Company has granted share options to subscribe for a total of 1,176,000 ordinary shares of the Company under the 2012 Share Option Scheme, and the closing price of the shares of the Company immediately before the date of which the options were granted was HK\$2.06.

於二零二二年四月二十五日，本公司已根據二零一二年購股權計劃授出可認購合共1,176,000股本公司普通股的購股權，緊接購股權授出日期前的本公司股份收市價為2.06港元。

Particulars of share options

購股權詳情

Date of grant 授出日期	Exercise period 行使期	Exercise price per share 每股行使價 HK\$ 港元
08.10.2012 二零一二年十月八日	(i) 259,500 options exercisable not less than 6 months from date of grant but not more than 10 years, i.e. 08.04.2013 – 07.10.2022 (i) 259,500份購股權可在自授出日期起計不少於六個月但不多於十年，即由二零一三年四月八日至二零二二年十月七日期間內行使 (ii) 259,500 options exercisable not less than 15 months from date of grant but not more than 10 years, i.e. 08.01.2014 – 07.10.2022 (ii) 259,500份購股權可在自授出日期起計不少於十五個月但不多於十年，即由二零一四年一月八日至二零二二年十月七日期間內行使 (iii) 1,160,000 options exercisable during the period from 08.10.2013 – 07.10.2022 (iii) 1,160,000份購股權可於二零一三年十月八日至二零二二年十月七日期間內行使 (iv) 2,230,000 options exercisable during the period from 08.10.2014 – 07.10.2022 (iv) 2,230,000份購股權可於二零一四年十月八日至二零二二年十月七日期間內行使 (v) 2,650,000 options exercisable during the period from 08.10.2015 – 07.10.2022 (v) 2,650,000份購股權可於二零一五年十月八日至二零二二年十月七日期間內行使	4.996

Date of grant	Exercise period	Exercise price per share
授出日期	行使期	每股行使價 HK\$ 港元
05.04.2013 二零一三年四月五日	(i) 50% exercisable not less than 6 months from date of grant but not more than 10 years, i.e. 05.10.2013 – 04.04.2023 (i) 當中的50%可在自授出日期起計不少於六個月但不多於十年，即由二零一三年十月五日至二零二三年四月四日期間內行使 (ii) unexercised balance thereof be exercisable not less than 15 months from date of grant but not more than 10 years, i.e. 05.07.2014 – 04.04.2023 (ii) 尚未行使的餘額可在自授出日期起計不少於十五個月但不多於十年，即由二零一四年七月五日至二零二三年四月四日期間內行使	5.620
30.12.2013 二零一三年十二月三十日	(i) 1,614,000 options: 50% exercisable not less than 6 months but not more than 10 years from the date of grant, i.e. 30.06.2014 – 29.12.2023; and in respect of the unexercised balance thereof be exercisable not less than 15 months but not more than 10 years from the date of grant, i.e. 30.03.2015 – 29.12.2023 (i) 1,614,000份購股權：當中之50%可在自授出日期起計不少於六個月但不多於十年，即由二零一四年六月三十日至二零二三年十二月二十九日期間內行使；及就其尚未行使之餘額而言，可在自授出日期起計不少於十五個月但不多於十年，即由二零一五年三月三十日至二零二三年十二月二十九日期間內行使 (ii) 669,000 options will be exercisable during the period from 30.12.2014 – 29.12.2023 (ii) 669,000份購股權可於二零一四年十二月三十日至二零二三年十二月二十九日期間內行使 (iii) 669,000 options will be exercisable during the period from 30.12.2015 – 29.12.2023 (iii) 669,000份購股權可於二零一五年十二月三十日至二零二三年十二月二十九日期間內行使 (iv) 702,000 options will be exercisable during the period from 30.12.2016 – 29.12.2023 (iv) 702,000份購股權可於二零一六年十二月三十日至二零二三年十二月二十九日期間內行使	7.300

Date of grant 授出日期	Exercise period 行使期	Exercise price per share 每股行使價 HK\$ 港元
07.10.2014 二零一四年十月七日	(i) 600,000 options: 50% will be exercisable during the period from 30.06.2015 - 06.10.2024; and 50% will be exercisable during the period from 30.06.2016 - 06.10.2024	10.340
	(i) 600,000份購股權：當中的50%可於二零一五年六月三十日至二零二四年十月六日期間內行使；及50%可於二零一六年六月三十日至二零二四年十月六日期間內行使	
	(ii) 250,000 options will be exercisable during the period from 03.10.2015 - 06.10.2024	
	(ii) 250,000份購股權可於二零一五年十月三日至二零二四年十月六日期間內行使	
	(iii) 250,000 options will be exercisable during the period from 03.10.2016 - 06.10.2024	
	(iii) 250,000份購股權可於二零一六年十月三日至二零二四年十月六日期間內行使	
	(iv) 250,000 options will be exercisable during the period from 03.10.2017 - 06.10.2024	
	(iv) 250,000份購股權可於二零一七年十月三日至二零二四年十月六日期間內行使	
31.03.2015 二零一五年三月三十一日	(i) 669,000 options will be exercisable during the period from 30.09.2015 - 30.03.2025	11.200
	(i) 669,000份購股權可於二零一五年九月三十日至二零二五年三月三十日期間內行使	
	(ii) 669,000 options will be exercisable during the period from 30.06.2016 - 30.03.2025	
	(ii) 669,000份購股權可於二零一六年六月三十日至二零二五年三月三十日期間內行使	
31.03.2016 二零一六年三月三十一日	(i) 880,500 options will be exercisable during the period from 30.09.2016 - 30.03.2026	5.754
	(i) 880,500份購股權可於二零一六年九月三十日至二零二六年三月三十日期間內行使	
	(ii) 880,500 options will be exercisable during the period from 30.06.2017 - 30.03.2026	
	(ii) 880,500份購股權可於二零一七年六月三十日至二零二六年三月三十日期間內行使	

Date of grant 授出日期	Exercise period 行使期	Exercise price per share 每股行使價 HK\$ 港元
13.04.2017 二零一七年四月十三日	(i) 885,000 options will be exercisable during the period from 13.10.2017 – 12.04.2027	7.548
	(i) 885,000份購股權可於二零一七年十月十三日至二零二七年四月十二日期間內行使	
	(ii) 885,000 options will be exercisable during the period from 13.07.2018 – 12.04.2027	
	(ii) 885,000份購股權可於二零一八年七月十三日至二零二七年四月十二日期間內行使	
03.10.2017 二零一七年十月三日	(i) 250,000 options will be exercisable during the period from 03.10.2018 – 02.10.2027	6.190
	(i) 250,000份購股權可於二零一八年十月三日至二零二七年十月二日期間內行使	
	(ii) 250,000 options will be exercisable during the period from 03.10.2019 – 02.10.2027	
	(ii) 250,000份購股權可於二零一九年十月三日至二零二七年十月二日期間內行使	
	(iii) 250,000 options will be exercisable during the period from 03.10.2020 – 02.10.2027	
	(iii) 250,000份購股權可於二零二零年十月三日至二零二七年十月二日期間內行使	
	(iv) 500,000 options will be exercisable during the period from 03.10.2021 – 02.10.2027	
	(iv) 500,000份購股權可於二零二一年十月三日至二零二七年十月二日期間內行使	
13.04.2018 二零一八年四月十三日	(i) 684,000 options will be exercisable during the period from 13.10.2018 – 12.04.2028	11.216
	(i) 684,000份購股權可於二零一八年十月十三日至二零二八年四月十二日期間內行使	
	(ii) 684,000 options will be exercisable during the period from 13.07.2019 – 12.04.2028	
	(ii) 684,000份購股權可於二零一九年七月十三日至二零二八年四月十二日期間內行使	

Date of grant 授出日期	Exercise period 行使期	Exercise price per share 每股行使價 HK\$ 港元
15.04.2019 二零一九年四月十五日	(i) 888,000 options will be exercisable during the period from 15.10.2019 – 14.04.2029	7.324
	(i) 888,000份購股權可於二零一九年十月十五日至二零二九年四月十四日期間內行使	
	(ii) 888,000 options will be exercisable during the period from 15.07.2020 – 14.04.2029	
	(ii) 888,000份購股權可於二零二零年七月十五日至二零二九年四月十四日期間內行使	
15.04.2020 二零二零年四月十五日	(i) 882,000 options will be exercisable during the period from 15.10.2020 – 14.04.2030	3.648
	(i) 882,000份購股權可於二零二零年十月十五日至二零三零年四月十四日期間內行使	
	(ii) 882,000 options will be exercisable during the period from 15.07.2021 – 14.04.2030	
	(ii) 882,000份購股權可於二零二一年七月十五日至二零三零年四月十四日期間內行使	
	(iii) 3,525,000 options will be exercisable during the period from 15.10.2021 – 14.04.2030	
	(iii) 3,525,000份購股權可於二零二一年十月十五日至二零三零年四月十四日期間內行使	
	(iv) 3,525,000 options will be exercisable during the period from 15.04.2023 – 14.04.2030	
	(iv) 3,525,000份購股權可於二零二三年四月十五日至二零三零年四月十四日期間內行使	

Date of grant 授出日期	Exercise period 行使期	Exercise price per share 每股行使價 HK\$ 港元
23.10.2020 二零二零年十月二十三日	(i) 500,000 options will be exercisable during the period from 23.10.2021 to 22.10.2030	5.310
	(i) 500,000份購股權可於二零二一年十月二十三日至二零三零年十月二十二日期間內行使	
	(ii) 500,000 options will be exercisable during the period from 23.10.2022 to 22.10.2030	
	(ii) 500,000份購股權可於二零二二年十月二十三日至二零三零年十月二十二日期間內行使	
	(iii) 500,000 options will be exercisable during the period from 23.10.2023 to 22.10.2030	
	(iii) 500,000份購股權可於二零二三年十月二十三日至二零三零年十月二十二日期間內行使	
	(iv) 500,000 options will be exercisable during the period from 23.10.2024 to 22.10.2030	
	(iv) 500,000份購股權可於二零二四年十月二十三日至二零三零年十月二十二日期間內行使	
21.04.2021 二零二一年四月二十一日	(i) 882,000 options will be exercisable during the period from 21.10.2021 – 20.04.2031	5.806
	(i) 882,000份購股權可於二零二一年十月二十一日至二零三一年四月二十日期間內行使	
	(ii) 882,000 options will be exercisable during the period from 21.07.2022 – 20.04.2031	
	(ii) 882,000份購股權可於二零二二年七月二十一日至二零三一年四月二十日期間內行使	
25.04.2022 二零二二年四月二十五日	(i) 588,000 options will be exercisable during the period from 25.10.2022 – 24.04.2032	2.076
	(i) 588,000份購股權可於二零二二年十月二十五日至二零三二年四月二十四日期間內行使	
	(ii) 588,000 options will be exercisable during the period from 25.07.2023 – 24.04.2032	
	(ii) 588,000份購股權可於二零二三年七月二十五日至二零三二年四月二十四日期間內行使	

DIRECTORS' RIGHT TO ACQUIRE SHARES

Save as the interest disclosed in the section headed "Directors' and Chief Executive's Interests in Securities" below, at no time during the period ended 30 June 2022 was the Company or any of its subsidiaries a party to any arrangement to enable the Directors or chief executive of the Company or their respective spouses or children under 18 years of age or their associates to acquire benefits by means of the acquisition of shares in the Company or any other body corporate.

董事購入股份的權利

除下文「董事及最高行政人員於證券的權益」一節所披露的權益以外，本公司及其任何附屬公司均無於截至二零二二年六月三十日止期間內任何時間作出任何安排，致使本公司董事或最高行政人員或彼等各自的配偶或未滿18歲子女或彼等的聯繫人可藉購入本公司或任何其他法人團體的股份而得益。

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS IN SECURITIES

As at 30 June 2022, the directors and the chief executive of the Company and their associates had the following interest in the shares and underlying shares of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")), as recorded in the register required to be kept under Section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") as set out in Appendix 10 to the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules").

董事及最高行政人員於證券的權益

於二零二二年六月三十日，本公司董事及最高行政人員及彼等的聯繫人於本公司及其相聯法團(定義見證券及期貨條例第XV部)的股份及相關股份中擁有以下已記錄於根據證券及期貨條例第352條須存置的登記冊，或根據聯交所證券上市規則(「上市規則」)附錄十所載上市發行人董事進行證券交易的標準守則(「標準守則」)已另行知會本公司及聯交所的權益。

(a) Long position in shares of the Company ("Shares")

(a) 本公司股份(「股份」)的好倉

Name of director 董事姓名	Nature of interest 權益性質	Number of ordinary shares held 所持普通股數目	Total 總計	Approximate percentage of shareholding 持股概約百分比
Lee Siu Fong 李小芳	Beneficial owner 實益擁有人	875		
	Interest held jointly with Leelalertsuphakun Wanee 與李焯妮共同持有之權益	1,600,000		
	Interest of a controlled corporation (Note 1) 一間受控制法團的權益 (附註1)	114,000,625	115,601,500	19.63%
Leelalertsuphakun Wanee 李焯妮	Beneficial owner 實益擁有人	4,843,000		
	Interest held jointly with Lee Siu Fong 與李小芳共同持有之權益	1,600,000		
	Interest of a controlled corporation (Note 1) 一間受控制法團的權益 (附註1)	114,000,625	120,443,625	20.45%

Name of director 董事姓名	Nature of interest 權益性質	Number of ordinary shares held 所持普通股數目	Total 總計	Approximate percentage of shareholding 持股概約百分比
Li Xiaoyi 李小翊	Beneficial owner 實益擁有人	41,092,766		
	Family interest (Note 2) 家族權益(附註2)	16,000,000		
	Others 其他	1,920,385	59,013,151	10.02%
Chan Yau Ching, Bob 陳友正	Beneficial owner 實益擁有人	520,000	520,000	0.09%
Lam Yat Cheong 林日昌	Beneficial owner 實益擁有人	300,000	300,000	0.05%
Tsim Wah Keung, Karl 詹華強	Beneficial owner 實益擁有人	300,000	300,000	0.05%

Notes:

附註：

- (1) 114,000,625 Shares are held through Huby Technology Limited (“**Huby Technology**”). Huby Technology is an investment holding company jointly owned by Ms. Lee Siu Fong and Ms. Leelalertsuphakun Wanee.
- (2) These Shares are held by High Knowledge Investments Limited which is wholly owned by Dr. Li Xiaoyi’s spouse, Ms. Lue Shuk Ping, Vicky (“**Ms. Lue**”). The interest held by Ms. Lue is deemed to be part of the interest of Dr. Li Xiaoyi.

- (1) 114,000,625 股股份乃透過 Huby Technology Limited (「**Huby Technology**」) 持有。Huby Technology 為一間投資控股公司，由李小芳女士及李燁妮女士共同擁有。
- (2) 該等股份由 High Knowledge Investments Limited 持有。該公司由李小翊博士的配偶呂淑冰女士(「**呂女士**」)全資擁有。呂女士持有的權益被視作李小翊博士的部分權益。

(b) Long position in underlying Shares – share options of the Company

Under the share option schemes of the Company, the following Directors of the Company have personal interest in options to subscribe for the Shares. Details of the share options granted to them are as follows:

(b) 於相關股份的好倉—本公司購股權

根據本公司的購股權計劃，下列董事於可認購股份的購股權中擁有個人權益。授予彼等的購股權詳情如下：

Name of director	Date of grant	Exercise period	Balance as at	During the period		Balance as at	Exercise price per share
			1 January 2022	Granted	Exercised	30 June 2022	
董事姓名	授出日期	行使期 (Notes) (附註)	於二零二二年一月一日之結餘	已授出	已行使	於二零二二年六月三十日之結餘	每股行使價 HK\$ 港元
Lee Siu Fong	30 December 2013	(1)	538,000	-	-	538,000	7.300
李小芳	二零一三年十二月三十日						
	31 March 2015	(2)	446,000	-	-	446,000	11.200
	二零一五年三月三十一日						
	31 March 2016	(3)	587,000	-	-	587,000	5.754
	二零一六年三月三十一日						
	13 April 2017	(4)	590,000	-	-	590,000	7.548
	二零一七年四月十三日						
	13 April 2018	(5)	456,000	-	-	456,000	11.216
	二零一八年四月十三日						
	15 April 2019	(6)	592,000	-	-	592,000	7.324
	二零一九年四月十五日						
	15 April 2020	(7)	588,000	-	-	588,000	3.648
	二零二零年四月十五日						
	21 April 2021	(8)	588,000	-	-	588,000	5.806
	二零二一年四月二十一日						
	25 April 2022	(9)	-	588,000	-	588,000	2.076
	二零二二年四月二十五日						
			4,385,000	588,000	-	4,973,000	

Name of director	Date of grant	Exercise period	Balance as at	During the period		Balance as at	Exercise price per share
			1 January 2022	Granted	Exercised	30 June 2022	
董事姓名	授出日期	行使期 (Notes) (附註)	於二零二二年一月一日之結餘	已授出	已行使	於二零二二年六月三十日之結餘	每股行使價 HK\$ 港元
Leelalertsuphakun Wanee 李萍妮	30 December 2013 二零一三年十二月三十日	(1)	338,000	-	-	338,000	7.300
	31 March 2015 二零一五年三月三十一日	(2)	446,000	-	-	446,000	11.200
	31 March 2016 二零一六年三月三十一日	(3)	587,000	-	-	587,000	5.754
	13 April 2017 二零一七年四月十三日	(4)	590,000	-	-	590,000	7.548
	13 April 2018 二零一八年四月十三日	(5)	456,000	-	-	456,000	11.216
	15 April 2019 二零一九年四月十五日	(6)	592,000	-	-	592,000	7.324
	15 April 2020 二零二零年四月十五日	(7)	588,000	-	-	588,000	3.648
	21 April 2021 二零二一年四月二十一日	(8)	588,000	-	-	588,000	5.806
	25 April 2022 二零二二年四月二十五日	(9)	-	588,000	-	588,000	2.076
			4,185,000	588,000	-	4,773,000	
Li Xiaoyi 李小平	31 March 2015 二零一五年三月三十一日	(2)	446,000	-	-	446,000	11.200
	31 March 2016 二零一六年三月三十一日	(3)	587,000	-	-	587,000	5.754
	13 April 2017 二零一七年四月十三日	(4)	590,000	-	-	590,000	7.548
	13 April 2018 二零一八年四月十三日	(5)	456,000	-	-	456,000	11.216
	15 April 2019 二零一九年四月十五日	(6)	592,000	-	-	592,000	7.324
	15 April 2020 二零二零年四月十五日	(7)	588,000	-	-	588,000	3.648
	21 April 2021 二零二一年四月二十一日	(8)	588,000	-	-	588,000	5.806
			3,847,000	-	-	3,847,000	

Notes:

- (1) Divided into 2 tranches exercisable from 30 June 2014 and 30 March 2015 respectively to 29 December 2023.
- (2) Divided into 2 tranches exercisable from 30 September 2015 and 30 June 2016 respectively to 30 March 2025.
- (3) Divided into 2 tranches exercisable from 30 September 2016 and 30 June 2017 respectively to 30 March 2026.
- (4) Divided into 2 tranches exercisable from 13 October 2017 and 13 July 2018 respectively to 12 April 2027.
- (5) Divided into 2 tranches exercisable from 13 October 2018 and 13 July 2019 respectively to 12 April 2028.
- (6) Divided into 2 tranches exercisable from 15 October 2019 and 15 July 2020 respectively to 14 April 2029.
- (7) Divided into 2 tranches exercisable from 15 October 2020 and 15 July 2021 respectively to 14 April 2030.
- (8) Divided into 2 tranches exercisable from 21 October 2021 and 21 July 2022 respectively to 20 April 2031.
- (9) Divided into 2 tranches exercisable from 25 October 2022 and 25 July 2023 respectively to 24 April 2032.

(c) As at 30 June 2022, Dr. Li Xiaoyi had beneficial interest in (a) 12,740 ordinary shares in Powder Pharmaceuticals Incorporated; and (b) 830 share options which can be converted into 830 ordinary shares of Powder Pharmaceuticals Incorporated when exercised.

附註：

- (1) 分拆成2批，分別可由二零一四年六月三十日及二零一五年三月三十日起至二零二三年十二月二十九日止行使。
- (2) 分拆成2批，分別可由二零一五年九月三十日及二零一六年六月三十日起至二零二五年三月三十日止行使。
- (3) 分拆成2批，分別可由二零一六年九月三十日及二零一七年六月三十日起至二零二六年三月三十日止行使。
- (4) 分拆成2批，分別可由二零一七年十月十三日及二零一八年七月十三日起至二零二七年四月十二日止行使。
- (5) 分拆成2批，分別可由二零一八年十月十三日及二零一九年七月十三日起至二零二八年四月十二日止行使。
- (6) 分拆成2批，分別可由二零一九年十月十五日及二零二零年七月十五日起至二零二九年四月十四日止行使。
- (7) 分拆成2批，分別可由二零二零年十月十五日及二零二一年七月十五日起至二零二零年四月十四日止行使。
- (8) 分拆成2批，分別可由二零二一年十月二十一日及二零二二年七月二十一日起至二零三一年四月二十日止行使。
- (9) 分拆成2批，分別可由二零二二年十月二十五日及二零二三年七月二十五日起至二零三二年四月二十四日止行使。

(c) 於二零二二年六月三十日，李小平博士(a)於普樂藥業有限公司的12,740股普通股中；及(b)於在行使時可轉換為830股普樂藥業有限公司普通股的830份購股權中擁有實益權益。

- (d)** As at 30 June 2022, Dr. Li Xiaoyi had beneficial interest in 14,022,800 share options which can be converted into 14,022,800 ordinary shares of Zhaoke Ophthalmology Limited (“ZKO”), an associated corporation within the meaning of Part XV of the SFO, when exercised. Dr. Li Xiaoyi spouse’s, Ms. Lue, had beneficial interest in 166,666 ordinary shares of ZKO. The interest held by Ms. Lue is deemed to be part of the interest of Dr. Li Xiaoyi. Dr. Li Xiaoyi holds 65% of the equity interest of Lee’s Healthcare Industry Investments Limited, which in turn is the general partner of Lee’s Healthcare Industry Fund L.P. For the purpose of the SFO, Dr. Li Xiaoyi is deemed to have an interest in the 2,187,600 ordinary shares of ZKO held by Lee’s Healthcare Industry Fund L.P..
- (d)** 於二零二二年六月三十日，李小羿博士於在行使時可轉換為14,022,800股兆科眼科有限公司（「兆科眼科」）（按證券及期貨條例第XV部所界定為相聯法團）普通股的14,022,800份購股權中擁有實益權益。李小羿博士的配偶呂女士於166,666股兆科眼科普通股中擁有實益權益。呂女士持有的權益被視為李小羿博士的部分權益。李小羿博士持有Lee’s Healthcare Industry Investments Limited的65%股權，而Lee’s Healthcare Industry Investments Limited為Lee’s Healthcare Industry Fund L.P.的普通合夥人。根據證券及期貨條例，李小羿博士被視為於Lee’s Healthcare Industry Fund L.P.持有的2,187,600股兆科眼科普通股中擁有權益。
- (e)** As at 30 June 2022, Ms. Leelalertsuphakun Wanee had beneficial interest in 23,557 ordinary shares of ZKO.
- (e)** 於二零二二年六月三十日，李燁妮女士於23,557股兆科眼科普通股中擁有實益權益。
- (f)** As at 30 June 2022, Dr. Chan Yau Ching, Bob, had beneficial interest in 1,000 ordinary shares of ZKO. Ms. Chan Sau Lin, the spouse of Dr. Chan Yau Ching, Bob, had beneficial interest in 1,000 ordinary shares of ZKO. The interest held by the spouse of Dr. Chan Yau Ching, Bob, is deemed to be part of the interest of Dr. Chan Yau Ching, Bob.
- (f)** 於二零二二年六月三十日，陳友正博士於1,000股兆科眼科普通股中擁有實益權益。陳友正博士的配偶陳秀蓮女士於1,000股兆科眼科普通股中擁有實益權益。陳友正博士配偶持有的權益被視為陳友正博士的部分權益。
- (g)** As at 30 June 2022, Mr. Lam Yat Cheong had beneficial interest in 3,000 ordinary shares of ZKO.
- (g)** 於二零二二年六月三十日，林日昌先生於3,000股兆科眼科普通股中擁有實益權益。
- (h)** As at 30 June 2022, Dr. Tsim Wah Keung, Karl, had beneficial interest in 34,323 ordinary shares of ZKO.
- (h)** 於二零二二年六月三十日，詹華強博士於34,323股兆科眼科普通股中擁有實益權益。

(i) Save as disclosed above, no interests and short positions were held or deemed to be taken to be held under Part XV of the SFO by any director or chief executive of the Company or their respective associates in the Shares and the underlying shares of the Company or any of its associated corporations which were required to be notified to the Company and the Stock Exchange pursuant to Part XV of the SFO or pursuant to the Model Code, or which are required pursuant to Section 352 of the SFO to be entered in the register referred to therein.

(i) 除上文所披露者外，本公司任何董事或最高行政人員或彼等各自的聯繫人概無於本公司或其任何相聯法團的股份及相關股份中持有或根據證券及期貨條例第XV部被視為持有任何權益及淡倉，而須根據證券及期貨條例第XV部或標準守則知會本公司及聯交所或須根據證券及期貨條例第352條記入該條所指的登記冊。

SUBSTANTIAL SHAREHOLDERS' INTEREST IN SECURITIES

As at 30 June 2022, the following parties (other than a director or chief executive of the Company) who had interests or short positions in the Shares and underlying shares of the Company which are required to be notified to the Company pursuant to Divisions 2 and 3 of Part XV of the SFO and required to be entered into the register maintained by the Company pursuant to Section 336 of the SFO:

(a) Long position in Shares

Name 姓名／名稱	Capacity 身份	Number of ordinary shares held 所持普通股數目	Approximate percentage of shareholding 持股概約百分比
Huby Technology Limited	Beneficial owner 實益擁有人	114,000,625	19.36%
Assicurazioni Generali S.p.A.	Interest of a controlled corporation 一間受控制法團之權益	81,405,000	13.82%
Assicurazioni Generali S.p.A.	一間受控制法團之權益		
Li Zhenfu	Interest of a controlled corporation 一間受控制法團之權益	81,405,000	13.82%
Li Zhenfu	一間受控制法團之權益		

主要股東於證券的權益

於二零二二年六月三十日，下列人士(本公司董事或最高行政人員除外)於本公司的股份及相關股份中擁有根據證券及期貨條例第XV部第2及3分部須知會本公司，以及根據證券及期貨條例第336條須記錄在本公司所置存登記冊的權益或淡倉：

(a) 股份好倉

Name 姓名／名稱	Capacity 身份	Number of ordinary shares held 所持普通股數目	Approximate percentage of shareholding 持股概約百分比
Lion River I N.V.	Interest of a controlled corporation	81,405,000	13.82%
Lion River I N.V.	一間受控制法團之權益		
GL Partners Capital Management Limited	Interest of a controlled corporation	76,165,488	12.93%
GL Partners Capital Management Limited	一間受控制法團之權益		
Apta Finance S.A.	Interest of a controlled corporation	70,771,898	12.02%
Apta Finance S.A.	一間受控制法團之權益		
Cavazza Paolo	Interest of a controlled corporation	70,771,898	12.02%
Cavazza Paolo	一間受控制法團之權益		
Paponi Claudia	Family interest	70,771,898	12.02%
Paponi Claudia	家族權益		
Qualister SA	Beneficial owner	64,867,577	11.02%
Qualister SA	實益擁有人		
GSR Capital Joy Corporation	Beneficial owner	34,566,935	5.87%
GSR Capital Joy Corporation	實益擁有人		
GoldenSand Capital Ltd	Interest of a controlled corporation	34,566,935	5.87%
GoldenSand Capital Ltd	一間受控制法團之權益		
Wu Sonny	Interest of a controlled corporation	34,566,935	5.87%
Wu Sonny	一間受控制法團之權益		
High Knowledge Investments Limited	Beneficial owner (Note 1)	16,000,000	2.72%
High Knowledge Investments Limited	實益擁有人(附註1)		
Lue Shuk Ping, Vicky	Interest of a controlled corporation (Note 2)	16,000,000	2.72%
呂淑冰	一間受控制法團之權益 (附註2)		
	Family interest (Note 3) 家族權益(附註3)	43,013,151	7.30%

Notes:

- (1) These Shares are legally owned by High Knowledge Investments Limited, which is entirely and beneficially owned by Dr. Li Xiaoyi's spouse, Ms. Lue.
- (2) These Shares are owned by Ms. Lue's spouse, Dr. Li Xiaoyi.

附註：

- (1) 該等股份在法律上由 High Knowledge Investments Limited 擁有，該公司由李小羿博士的配偶呂女士全資及實益擁有。
- (2) 該等股份由呂女士的配偶李小羿博士擁有。

(b) Long position in underlying shares – share options of the Company

(b) 於相關股份的好倉—本公司購股權

Name 姓名／名稱	Capacity 身份	Number of ordinary shares held 所持普通股數目	Approximate percentage of shareholding 持股概約百分比
Lue Shuk Ping, Vicky 呂淑冰	Family interest (Note 1) 家族權益(附註1)	3,847,000	0.65%

Note:

- (1) These share options are owned by Ms. Lue's spouse, Dr. Li Xiaoyi.

附註：

- (1) 該等購股權由呂女士的配偶李小羿博士擁有。

(c) Short position in Shares

(c) 於股份的淡倉

No short positions of other persons and substantial shareholders in the Shares or underlying shares of the Company and its associated corporations were recorded in the register.

登記冊中概無記錄其他人士及主要股東於本公司及其相聯法團的股份或相關股份中的淡倉。

Saved as disclosed above, as at 30 June 2022, the Directors are not aware of any other person or corporation having an interest or short position in Shares and underlying shares of the Company which fall to be disclosed under the provisions of Divisions 2 and 3 of Part XV of the SFO.

除上文所披露者外，於二零二二年六月三十日，董事概不知悉任何其他人士或法團於本公司股份及相關股份擁有須根據證券及期貨條例第XV部第2及3分部的條文披露的權益或淡倉。

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities during the six months ended 30 June 2022.

INTERIM DIVIDEND

The Board recommended an interim dividend of HK\$0.010 (2021: HK\$0.030) per share to shareholders registered in the Company's register of members as at the close of business on Thursday, 15 September 2022.

CLOSURE OF REGISTER OF MEMBERS

The register of members will be closed from Tuesday, 13 September 2022 to Thursday, 15 September 2022 (both days inclusive). In order to establish entitlements to the interim dividend, all transfers accompanied by the relevant share certificates must be lodged with the share registrar of the Company in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Friday, 9 September 2022. Interim dividend will be paid on Tuesday, 27 September 2022 to shareholders registered in the Company's register of members as at the close of business on Thursday, 15 September 2022.

COMPETING INTERESTS

None of the Directors, the management shareholders or substantial shareholders of the Company or any of their respective associates has engaged in any business that competes or may compete, wither directly or indirectly, with the business of the Group, as defined in the Listing Rules, or has any other conflict of interests with the Group during the period ended 30 June 2021.

購買、出售或贖回上市證券

於截至二零二二年六月三十日止六個月，本公司或其任何附屬公司並無購買、出售或贖回本公司任何上市證券。

中期股息

董事會建議向於二零二二年九月十五日(星期四)營業時間結束時已於本公司股東名冊登記之股東派發中期股息每股0.010港元(二零二一年: 0.030港元)。

暫停辦理股份過戶登記

本公司將自二零二二年九月十三日(星期二)起至二零二二年九月十五日(星期四)止(包括首尾兩日)暫停辦理股份過戶登記。為確保享有收取中期股息之權利，所有過戶文件連同有關股票須於二零二二年九月九日(星期五)下午四時三十分或之前送至本公司香港股份登記處香港中央證券登記有限公司(地址為香港灣仔皇后大道東183號合和中心17樓1712-1716舖)。本公司將於二零二二年九月二十七日(星期二)向於二零二二年九月十五日(星期四)營業時間結束時在本公司股東名冊登記之股東派付中期股息。

競爭性權益

於截至二零二一年六月三十日止期間，本公司概無董事、管理層股東或主要股東或彼等各自之任何聯繫人從事(直接或間接)與或可能與本集團之業務構成競爭(定義見上市規則)之業務，或與本集團業務有任何其他利益衝突。

CORPORATE GOVERNANCE PRACTICES

A new Corporate Governance Code (the “**CG Code**”) as set out in Appendix 14 of the Listing Rules came into effect on 1 January 2022. A nomination committee of the Company comprising Ms. Lee Siu Fong as the chairman, Dr. Chan Yau Ching, Bob and Dr. Tsim Wah Keung, Karl as the members has been established by the Board with written terms of reference with effect from 2 January 2022, in which majority of the committee members are independent non-executive Directors and is chaired by the chairman of the Board. Since then, the Company has complied with code provision B.3.1 of the CG Code.

Pursuant to code provision B.3.4 of the CG Code, the Board should set out in the circular to shareholders and/or explanatory statement accompanying the notice of the general meeting when the Board proposes a resolution to elect an individual as an independent non-executive Directors at the relevant general meeting. The Company had not set out the explanatory statement in the circular published on 21 April 2022 relating to the re-election of independent non-executive Director. Mr. Lam Yat Cheong (“**Mr. Lam**”) has given confirmation of independence to the Company pursuant to Rule 3.13 of the Listing Rules. The nomination committee assessed and reviewed the independence of Mr. Lam. In view of the diversified knowledge, experience and skills of Mr. Lam in finance, operation, financial accounting, corporate governance and compliance, the nomination committee believes that his expertise will enable him to fulfil his roles as independent non-executive Director effectively and can provide useful and constructive opinion and make contribution to the Board and future development of the Company. Based on the background of Mr. Lam including but not limited to gender, cultural and educational background, ethnicity, professional experience, skills and knowledge, it is believed that Mr. Lam can contribute to diversity of the Board. The nomination committee and the Board are of the view that Mr. Lam has satisfied all the criteria for independence set out in Rule 3.13 of the Listing Rules.

企業管治常規

上市規則附錄十四所載之新企業管治守則（「**企管守則**」）於二零二二年一月一日生效。董事會已成立本公司之提名委員會，委員會由李小芳女士（擔任主席）、陳友正博士及詹華強博士（分別擔任成員）組成，訂有書面職權範圍，由二零二二年一月二日起生效，當中，大部分委員會成員為獨立非執行董事，並由董事會主席擔當主席。自此，本公司一直遵守企管守則之守則條文B.3.1。

根據企管守則之守則條文B.3.4，若董事會擬於股東大會上提呈決議案選任某人士為獨立非執行董事，有關股東大會通告所隨附之致股東通函及／或說明函件應予以列明。本公司於二零二二年四月二十一日刊發之通函內並無載列有關重選獨立非執行董事之說明函件。林日昌先生（「**林先生**」）已根據上市規則第3.13條向本公司提交獨立性確認書。提名委員會已評估及覆核林先生之獨立性。鑑於林先生於金融、營運、財務會計、企業管治及合規範疇擁有多元知識、經驗及技能，提名委員會相信其專長將有助其勝任獨立非執行董事之職位並提供有用有建設性之意見，以及對董事會及本公司之未來發展作出貢獻。基於林先生之背景（包括但不限於性別、文化及教育背景、種族、專業經驗、技能及知識），相信林先生可促進董事會成員多元化。提名委員會及董事會均認為，林先生符合上市規則第3.13條所列明之所有獨立性條件。

Pursuant to code provision B.2.3 of the CG Code, if an independent non-executive director has served more than nine years, such director's further appointment should be subject to a separate resolution to be approved by shareholders. The papers to shareholders accompanying that resolution should state why the Board (or the nomination committee) believes that the director is still independent and should be re-elected, including the factors considered, the process and the discussion of the board (or the nomination committee) in arriving at such determination. Mr. Lam has served the board for more than nine years and the Company had not set out in the circular published on 21 April 2022 relating to the re-election of Mr. Lam the reasons why the Board (or the nomination committee) believes that the director is still independent and should be re-elected independent non-executive Director.

根據企管守則之守則條文B.2.3，若獨立非執行董事在任已過九年，其是否獲續任應以獨立決議案形式由股東審議通過。隨附該決議案一同發給股東之文件中，應說明董事會(或提名委員會)為何認為該名董事仍屬獨立人士及應獲重選之原因，包括所考量之因素、董事會(或提名委員會)作此決定之過程及討論內容。林先生於董事會在任已過九年，而本公司於二零二二年四月二十一日刊發之通函內並無就重選林先生列明董事會(或提名委員會)為何認為該名董事仍屬獨立人士及應獲重選為獨立非執行董事之原因。

Mr. Lam is an independent non-executive Director serving the Company since 2004. The Board believes that Mr. Lam is considered as independent and continues to be independent because he has the required elements, character, integrity and experience to continue fulfilling the role of an independent non-executive Director by taking into account the factors set out in Rule 3.13 of the Listing Rules. Notwithstanding that Mr. Lam has served on the Board for more than nine years, the nomination committee and the Board are of the view that this does not and would not affect the exercise of his independent judgement as he has been providing objective views and independent opinions to the Company over the years. Mr. Lam has not engaged in the daily or executive management of the Group nor in any relationships or circumstances which would interfere with the exercise of his independent judgement. In addition, the Company has received from Mr. Lam a confirmation of independence pursuant to Rule 3.13 of the Listing Rules. Taking into consideration of Mr. Lam's independent scope of work and valuable contributions given to the Company in the past years, the Board considers Mr. Lam is able to provide independent, balanced and objective views to the Company's affairs and continue to independently fulfill his role as an independent non-executive Director despite the fact that he has served the Company for more than nine years. The nomination committee also considers that Mr. Lam could continue to contribute to the diversity of the Board with his past experience as independent non-executive director in other listed companies in Hong Kong and his professional experience in the auditing and accounting profession. Accordingly, the Board and the nomination committee recommended him for re-election as independent non-executive Director at the annual general meeting. A separate resolution has been proposed for Mr. Lam's re-election and he was re-elected as an independent non-executive Director in the annual general meeting held on 19 May 2022.

林先生自二零零四年起出任本公司之獨立非執行董事。董事會考慮上市規則第3.13條所載因素後相信，由於林先生具備繼續履行獨立非執行董事一職所需之要素、品格、誠信及經驗，故彼被視為獨立人士並繼續為獨立人士。儘管林先生已在董事會任職超過九年，惟提名委員會及董事會均認為此並無亦不會影響其行使獨立判斷，蓋因多年來彼一直向本公司提供客觀見解及獨立意見。林先生並無參與本集團之日常或行政管理，亦未涉及任何會妨礙其行使獨立判斷之關係或情況。此外，本公司已收到林先生根據上市規則第3.13條所發出之獨立性確認書。經考慮林先生多年來之獨立工作範圍及對本公司作出之寶貴貢獻後，董事會認為儘管林先生已於本公司服務超過九年，惟彼能為本公司之事務提供獨立、平衡及客觀之見解並可繼續獨立履行身為獨立非執行董事之職責。提名委員會亦認為，林先生憑藉過往於其他香港上市公司擔任獨立非執行董事之經驗以及於審核及會計界之專業經驗，將能繼續為董事會多元化作出貢獻。因此，董事會及提名委員會建議林先生在股東週年大會上重選連任獨立非執行董事，並已就其重選提呈獨立決議案。於二零二二年五月十九日舉行之股東週年大會上，林先生獲重選為獨立非執行董事。

Pursuant to code provision B.2.4 of the CG Code, the Company should disclose the length of tenure of each existing independent non-executive Directors on a named basis in the circular to shareholders and/or explanatory statement accompanying the notice of the annual general meeting where all of the independent non-executive Directors have served more than nine years on the Board. The Company has not set out such information in the circular published on 21 April 2022. The length of tenure of Dr. Chan Yau Ching, Bob, Mr. Lam and Dr. Tsim Wah Keung, Karl (each being an existing independent non-executive Director and all of them have been serving more than 9 years on the Board) as at the date of the circular was more than 20 years, 18 years and 18 years respectively.

Pursuant to code provision C.1.6 of the CG Code, independent non-executive directors and other non-executive directors should attend general meetings to gain and develop a balanced understanding of the views of shareholders. Our non-executive Directors and independent non-executive Directors had not attended the annual general meeting held on 19 May 2022 as they had other important prior engagement at the same time.

Save as disclosed above, the Company has complied with the CG Code to the Listing Rules throughout the six months ended 30 June 2022.

Looking forward, the Board will continue to conduct reviews on the Company's corporate governance practices from time to time to ensure compliance with the CG Code.

根據企管守則之守則條文B.2.4，若董事會內所有獨立非執行董事均在任超過九年，本公司應在股東週年大會通告所隨附之致股東通函及／或說明函件中披露每名在任獨立非執行董事之姓名及任期。本公司於二零二二年四月二十一日刊發之通函內並無載列有關資料。截至該通函日期，陳友正博士、林先生及詹華強博士（各人均為現任獨立非執行董事且已於董事會服務超過九年）之任期分別已超過二十年、十八年及十八年。

根據企管守則之守則條文C.1.6，獨立非執行董事及其他非執行董事應出席股東大會，以對股東之意見有全面、公正之了解。本公司之非執行董事及獨立非執行董事因較早前已安排其他要務在身而缺席於二零二二年五月十九日舉行之股東週年大會。

除上文所披露者外，本公司於截至二零二二年六月三十日止六個月內一直遵守企管守則。

日後，董事會將繼續不時審閱本公司之企業管治常規，以確保遵守企管守則。

As at the date of this report, the Board comprises the following directors:

Executive directors

Ms. Lee Siu Fong (*Chairman*)

Ms. Leelalertsuphakun Wanee

Non-executive directors

Dr. Li Xiaoyi

Mr. James Charles Gale

Independent non-executive directors

Dr. Chan Yau Ching, Bob

Mr. Lam Yat Cheong

Dr. Tsim Wah Keung, Karl

於本報告刊發日期，董事會由下列董事組成：

執行董事

李小芳女士(*主席*)

李燁妮女士

非執行董事

李小羿博士

James Charles Gale先生

獨立非執行董事

陳友正博士

林日昌先生

詹華強博士

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

承董事會命
李氏大藥廠控股有限公司
主席
李小芳

Hong Kong, 26 August 2022

香港，二零二二年八月二十六日

REPORT ON REVIEW OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

恒健會計師行有限公司

HLM CPA LIMITED

Certified Public Accountants

簡明綜合財務報表審閱報告

Rooms 1501–8, 15th Floor, Tai Yau Building
181 Johnston Road, Wanchai, Hong Kong
香港灣仔莊士敦道181號
大有大廈15樓1501–8室
Tel 電話: (852) 3103 6980
Fax 傳真: (852) 3104 0170
E-mail 電郵: info@hlm.com.hk

**TO THE BOARD OF DIRECTORS OF
LEE'S PHARMACEUTICAL HOLDINGS LIMITED**
*(Incorporated in the Cayman Islands with limited
liability)*

致李氏大藥廠控股有限公司董事會
(於開曼群島註冊成立的有限公司)

INTRODUCTION

We have reviewed the condensed consolidated financial statements of Lee's Pharmaceutical Holdings Limited (the "**Company**") and its subsidiaries (collectively referred to as the "**Group**") set out on pages 44 to 80, which comprise the condensed consolidated statement of financial position as of 30 June 2022 and the related condensed consolidated statement of profit or loss, condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended, and certain explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and Hong Kong Accounting Standard 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants. The directors of the Company are responsible for the preparation and presentation of these condensed consolidated financial statements in accordance with Hong Kong Accounting Standard 34.

緒言

吾等已審閱第44至第80頁所載的李氏大藥廠控股有限公司(「**貴公司**」)及其附屬公司(統稱「**貴集團**」)的簡明綜合財務報表，該等報表包括於二零二二年六月三十日的簡明綜合財務狀況表，以及截至該日止六個月期間的有關簡明綜合損益表、簡明綜合損益及其他全面收益表、簡明綜合權益變動表及簡明綜合現金流量表以及若干解釋附註。香港聯合交易所有限公司證券上市規則規定，中期財務資料的報告須按照其相關條文以及香港會計師公會頒佈的香港會計準則第34號「中期財務報告」編製。貴公司董事負責按照香港會計準則第34號編製及呈列簡明綜合財務報表。

Our responsibility is to express a conclusion, based on our review, on these condensed consolidated financial statements solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagement 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants. A review of these condensed consolidated financial statements consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated financial statements are not prepared, in all material respects, in accordance with Hong Kong Accounting Standard 34.

HLM CPA Limited
Certified Public Accountants

Chan Lap Chi
Practising Certificate number: P04084
Hong Kong, 26 August 2022

吾等的責任為根據吾等同意的受聘條款審閱此等簡明綜合財務報表，並按照吾等的審閱僅向閣下全體發表結論，除此之外，別無其他目的。吾等不就本報告的內容向任何其他人士承擔或負上任何責任。

審閱範圍

吾等根據香港會計師公會頒佈的《香港審閱工作準則》第2410號「實體的獨立核數師對中期財務資料的審閱」進行審閱。此等簡明綜合財務報表的審閱包括工作查詢（主要對負責財務及會計事務的人士），以及應用分析及其他審閱程序。審閱的範圍遠小於根據香港審核準則進行的審核，故吾等無法確保我們會知悉可通過審核辨別的所有重要事項。因此，吾等不會發表審核意見。

結論

根據吾等的審閱結果，吾等並無發現任何事項導致吾等相信簡明綜合財務報表在任何重大方面並未根據香港會計準則第34號編製。

恒健會計師有限公司
執業會計師

陳立志
執業證書編號：P04084
香港，二零二二年八月二十六日

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

簡明綜合損益表

For the three months and six months ended 30 June 2022

截至二零二二年六月三十日止三個月及六個月

		For the three months ended 30 June		For the six months ended 30 June		
		截至六月三十日止三個月		截至六月三十日止六個月		
		2022	2021	2022	2021	
		二零二二年	二零二一年	二零二二年	二零二一年	
Notes		HK\$'000	HK\$'000	HK\$'000	HK\$'000	
附註		千港元	千港元	千港元	千港元	
		(unaudited)	(unaudited)	(unaudited)	(unaudited)	
		(未經審核)	(未經審核)	(未經審核)	(未經審核)	
Revenue	收益	5	324,416	300,910	649,166	584,052
Cost of sales	銷售成本		(120,764)	(106,775)	(229,688)	(197,506)
Gross profit	毛利		203,652	194,135	419,478	386,546
Other income	其他收入	6	21,081	33,357	45,702	64,938
Other gains and losses, net	其他收益及虧損淨額		(5,346)	2,090,917	(5,227)	2,093,266
Selling and distribution expenses	銷售及分銷費用		(94,249)	(91,549)	(176,215)	(164,118)
Administrative expenses	行政費用		(53,796)	(65,330)	(111,075)	(124,201)
Net reversal of/(provision for) expected credit losses on financial assets	財務資產預期信貸虧損撥回/(撥備)淨額		3,931	(749)	(253)	(419)
Research and development expenses	研究及開發費用		(54,956)	(65,034)	(116,590)	(112,899)
Profit from operations	經營溢利		20,317	2,095,747	55,820	2,143,113
Finance costs	財務成本		(1,762)	(1,252)	(3,499)	(2,523)
Share of results of associates	分佔聯營公司業績		(271)	(1,047)	(526)	(3,311)
Profit before taxation	除稅前溢利	7	18,284	2,093,448	51,795	2,137,279
Taxation	稅項	8	(11,867)	4,098	(24,713)	(3,377)
Profit for the period	本期間溢利		6,417	2,097,546	27,082	2,133,902
Attributable to:	下列人士應佔：					
Owners of the Company	本公司擁有人		8,153	2,114,152	28,460	2,155,200
Non-controlling interests	非控股權益		(1,736)	(16,606)	(1,378)	(21,298)
			6,417	2,097,546	27,082	2,133,902
			HK cents	HK cents	HK cents	HK cents
			港仙	港仙	港仙	港仙
Earnings per share:	每股盈利：					
Basic	基本	10	1.38	359.07	4.83	366.24
Diluted	攤薄	10	1.38	358.92	4.83	366.00

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the three months and six months ended 30 June 2022

簡明綜合損益及其他全面收益表

截至二零二二年六月三十日止三個月及六個月

		For the three months ended 30 June		For the six months ended 30 June	
		截至六月三十日止三個月	2021	截至六月三十日止六個月	2021
		2022	2021	2022	2021
		二零二二年	二零二一年	二零二二年	二零二一年
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Profit for the period	本期間溢利	6,417	2,097,546	27,082	2,133,902
Other comprehensive (expense)/ income:	其他全面(開支)/收益：				
Items that may be reclassified subsequently to profit or loss:	其後可能重新分類至損益之項目：				
- Exchange differences on translation of financial statements of overseas subsidiaries	—換算海外附屬公司財務報表之匯兌差額	(57,638)	19,094	(49,811)	12,032
- Share of other comprehensive income of associates	—分佔聯營公司之其他全面收益	-	100	-	46
Item that will not be reclassified subsequently to profit or loss:	其後不會重新分類至損益之項目：				
- Fair value changes of financial assets at fair value through other comprehensive income	—按公平值透過其他全面收益列賬之財務資產之公平值變動	40,830	(690,631)	(291,865)	(781,827)
Other comprehensive expense for the period, net of tax	本期間其他全面開支，已扣除稅項	(16,808)	(671,437)	(341,676)	(769,749)
Total comprehensive (expense)/ income for the period	本期間全面(開支)/收益總額	(10,391)	1,426,109	(314,594)	1,364,153
Total comprehensive (expense)/ income for the period attributable to:	下列人士應佔本期間全面(開支)/收益總額：				
Owners of the Company	本公司擁有人	(7,136)	1,442,850	(310,998)	1,389,803
Non-controlling interests	非控股權益	(3,255)	(16,741)	(3,596)	(25,650)
		(10,391)	1,426,109	(314,594)	1,364,153

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 June 2022

簡明綜合財務狀況表

於二零二二年六月三十日

			30 June 2022 二零二二年 六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 HK\$'000 千港元 (audited) (經審核)
Non-current assets	非流動資產			
Property, plant and equipment	物業、廠房及設備	11	606,245	688,265
Intangible assets	無形資產	11	965,676	922,525
Goodwill	商譽		3,900	3,900
Interests in associates	於聯營公司之權益	12	5,741	6,267
Financial assets at fair value through profit or loss	按公平值透過損益列賬之財務資產		49,790	30,480
Financial assets at fair value through other comprehensive income	按公平值透過其他全面收益列賬之財務資產		717,261	1,006,717
Deferred tax assets	遞延稅項資產		12,387	15,424
			2,361,000	2,673,578
Current assets	流動資產			
Inventories	存貨		262,524	331,394
Trade receivables	應收貿易賬款	13	143,768	168,323
Other receivables, deposits and prepayments	其他應收款項、按金及預付款項		96,743	162,736
Advance to associates	墊付予聯營公司之款項		-	-
Tax recoverable	可收回稅項		11,088	23,338
Cash and bank balances	現金及銀行結餘		368,047	277,529
			882,170	963,320

		30 June 2022		31 December 2021
		二零二二年 六月三十日		二零二一年 十二月三十一日
		HK\$'000		HK\$'000
		千港元		千港元
		(unaudited)		(audited)
		(未經審核)		(經審核)
		Notes 附註		
Current liabilities	流動負債			
Trade payables	應付貿易賬款	14	66,691	62,599
Other payables and accruals	其他應付款項及應計費用		636,710	684,670
Bank borrowings	銀行借款	15	136,414	162,540
Lease liabilities	租賃負債		9,227	12,639
Tax payables	應付稅項		670	132
			849,712	922,580
Net current assets	流動資產淨值		32,458	40,740
Total assets less current liabilities	資產總值減流動負債		2,393,458	2,714,318
Capital and reserves	資本及儲備			
Share capital	股本	16	29,442	29,442
Reserves	儲備		2,112,233	2,435,136
Equity attributable to the owners of the Company	本公司擁有人應佔權益		2,141,675	2,464,578
Non-controlling interests	非控股權益		(77,012)	(73,416)
Total equity	總權益		2,064,663	2,391,162
Non-current liabilities	非流動負債			
Other payables and accruals	其他應付款項及應計費用		40,000	40,000
Bank borrowings	銀行借款	15	84,090	84,090
Lease liabilities	租賃負債		5,532	7,869
Retirement benefits	退休福利		114,570	111,970
Deferred tax liabilities	遞延稅項負債		84,603	79,227
			328,795	323,156
			2,393,458	2,714,318

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2022

簡明綜合權益變動表

截至二零二二年六月三十日止六個月

		Attributable to the owners of the Company 本公司擁有人應佔								Attributable to non-controlling interests		Total
		Share capital	Share premium	Merger difference	Share-based compensation reserve	Other reserves	Investments revaluation reserve	Exchange reserve	Retained profits	Sub-total	controlling interests	Total
		股本	股份溢價	合併差額	以股份支付之酬金儲備	其他儲備	投資重估儲備	匯兌儲備	保留溢利	小計	非控股權益	總計
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元
At 1 January 2022 (audited)	於二零二二年一月一日 (經審核)	29,442	720,091	9,200	55,964	65,302	(1,948,815)	22,838	3,510,556	2,464,578	(73,416)	2,391,162
Employee share option benefits	僱員購股權福利	-	-	-	6,349	-	-	-	-	6,349	-	6,349
Profit/(loss) for the period	本期間溢利/(虧損)	-	-	-	-	-	-	-	28,460	28,460	(1,378)	27,082
Other comprehensive expense for the period	本期間其他全面開支	-	-	-	-	-	-	-	-	-	-	-
- Exchange differences on translation of financial statements of overseas subsidiaries	- 換算海外附屬公司財務報表之匯兌差額	-	-	-	-	-	-	(49,453)	-	(49,453)	(358)	(49,811)
- Fair value changes of financial assets at fair value through other comprehensive income	- 按公平值透過其他全面收益列賬之財務資產之公平值變動	-	-	-	-	-	(290,005)	-	-	(290,005)	(1,860)	(291,865)
Total comprehensive (expense)/income for the period	本期間全面(開支)/收益總額	-	-	-	-	-	(290,005)	(49,453)	28,460	(310,998)	(3,596)	(314,594)
2021 final dividend paid	已付二零二一年末期股息	-	-	-	-	-	-	-	(18,254)	(18,254)	-	(18,254)
At 30 June 2022 (unaudited)	於二零二二年六月三十日 (未經審核)	29,442	720,091	9,200	62,313	65,302	(2,238,820)	(26,615)	3,520,762	2,141,675	(77,012)	2,064,663

Attributable to the owners of the Company
本公司擁有人應佔

		Share	Share	Merger	Share-	Other	Investments	Exchange	Retained	Sub-	Attributable	Total
		capital	premium	difference	based	reserves	revaluation	reserve	profits	total	to non-	
		股本	股份溢價	合併差額	compensation	其他儲備	投資重估	匯兌儲備	保留溢利	小計	controlling	
HK\$'000	HK\$'000	HK\$'000	reserve	以股份支付之	其他儲備	儲備	匯兌儲備	HK\$'000	HK\$'000	權益	HK\$'000	
		千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元
At 1 January 2021 (audited)	於二零二一年一月一日 (經審核)	29,406	714,813	9,200	40,847	65,228	(254,155)	(14,843)	1,559,299	2,149,795	(34,417)	2,115,378
Employee share option benefits	僱員購股權福利	-	-	-	8,498	-	-	-	-	8,498	-	8,498
Exercise of share options	行使購股權	36	5,278	-	(1,771)	-	-	-	-	3,543	-	3,543
Share of reserve of an associate	分佔一間聯營公司儲備	-	-	-	-	28	-	-	-	28	-	28
Profit/(loss) for the period	本期間溢利/(虧損)	-	-	-	-	-	-	-	2,155,200	2,155,200	(21,298)	2,133,902
Other comprehensive income/(expense) for the period	本期間其他全面收益/(開支)	-	-	-	-	-	-	-	-	-	-	-
- Exchange differences on translation of financial statements of overseas subsidiaries	- 換算海外附屬公司財務報表之匯兌差額	-	-	-	-	-	-	11,974	-	11,974	58	12,032
- Share of other comprehensive income of associates	- 分佔聯營公司之其他全面收益	-	-	-	-	46	-	-	-	46	-	46
- Fair value changes of financial assets at fair value through other comprehensive income	- 按公平值透過其他全面收益列賬之財務資產之公平值變動	-	-	-	-	-	(777,417)	-	-	(777,417)	(4,410)	(781,827)
Total comprehensive income/(expense) for the period	本期間全面收益/(開支)總額	-	-	-	-	46	(777,417)	11,974	2,155,200	1,389,803	(25,650)	1,364,153
2020 final dividend paid	已付二零二零年末期股息	-	-	-	-	-	-	-	(18,254)	(18,254)	-	(18,254)
At 30 June 2021 (unaudited)	於二零二一年六月三十日 (未經審核)	29,442	720,091	9,200	47,574	65,302	(1,031,572)	(2,869)	3,696,245	3,533,413	(60,067)	3,473,346

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2022

簡明綜合現金流量表

截至二零二二年六月三十日止六個月

For the six months ended
30 June

截至六月三十日止六個月

		2022	2021
		二零二二年	二零二一年
		HK\$'000	HK\$'000
		千港元	千港元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
Operating activities	經營業務		
Cash generated from operations	經營所產生之現金	254,731	175,703
Interest paid	已付利息	(2,513)	(1,727)
Income tax paid	已付所得稅	-	(28,011)
Net cash generated from operating activities	經營業務產生之現金淨額	252,218	145,965
Investing activities	投資活動		
Purchase of property, plant and equipment	購入物業、廠房及設備	(5,937)	(22,560)
Payment for construction in progress	在建工程付款	(1,161)	(3,355)
Additions to development cost and license fees	開發成本及專利費增加	(89,927)	(227,590)
Decrease in time deposits with initial terms of over three months	原期限超過三個月之定期存款減少	-	39,633
Other cash flows arising from investing activities	投資活動產生之其他現金流	(19,450)	(11,911)
Net cash used in investing activities	投資活動所用之現金淨額	(116,475)	(225,783)
Financing activities	融資活動		
Dividends paid	已付股息	(18,254)	(18,254)
Other cash flows arising from financing activities	融資活動產生之其他現金流	(32,295)	12,378
Net cash used in financing activities	融資活動所用之現金淨額	(50,549)	(5,876)

**For the six months ended
30 June**

截至六月三十日止六個月

2022

2021

二零二二年

二零二一年

HK\$'000

HK\$'000

千港元

千港元

(unaudited)

(unaudited)

(未經審核)

(未經審核)

Net increase/(decrease) in cash and cash equivalents	現金及現金等值 增加/(減少) 淨額	85,194	(85,694)
Cash and cash equivalents at 1 January	於一月一日之現金及 現金等值	277,529	375,199
Effect of foreign exchange rate changes	外幣匯率變動之影響	5,324	5,342
Cash and cash equivalents at 30 June	於六月三十日之現金及 現金等值	368,047	294,847
Analysis of cash and cash equivalents:	現金及現金等值分析：		
Cash and bank balances	現金及銀行結餘	368,047	282,447
Time deposits	定期存款	-	12,400
		368,047	294,847

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2022

未經審核簡明綜合財務報表附註

截至二零二二年六月三十日止六個月

1. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements have been prepared in accordance with Hong Kong Accounting Standard (“HKAS”) 34 “Interim Financial Reporting” issued by the Hong Kong Institute of Certified Public Accountants (the “HKICPA”) as well as with the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

2. PRINCIPAL ACCOUNTING POLICIES

The unaudited condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values as appropriate.

The unaudited condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual financial statements for the year ended 31 December 2021.

The accounting policies and methods of computation used in preparing the unaudited condensed consolidated financial statements for the six months ended 30 June 2022 are consistent with those used in the Group’s annual financial statements for the year ended 31 December 2021 except as described below.

1. 編製基準

未經審核簡明綜合財務報表乃按照香港會計師公會頒佈之香港會計準則第34號「中期財務報告」及香港聯合交易所有限公司證券上市規則（「上市規則」）附錄十六之適用披露規定編製。

2. 主要會計政策

未經審核簡明綜合財務報表乃按歷史成本基準編製，惟若干財務工具按公平值計量（視適當情況而定）。

未經審核簡明綜合財務報表不包括須於全年財務報表提供之所有資料及披露事項，並應與本集團截至二零二一年十二月三十一日止年度之全年財務報表一併閱讀。

編製截至二零二二年六月三十日止六個月之未經審核簡明綜合財務報表所用之會計政策及計算方法與本集團截至二零二一年十二月三十一日止年度之全年財務報表所用者一致，惟下述者除外。

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

In the current reporting period, the Group has applied the following amendments to HKFRS issued by the HKICPA for the first time which are mandatorily effective for the annual periods beginning on or after 1 January 2022 for the preparation of the Group's unaudited condensed consolidated financial statements. HKFRS comprise Hong Kong Financial Reporting Standards; HKASs; and HK (IFRIC) Interpretations, HK Interpretations and HK (SIC) Interpretations.

Amendments to HKAS 16	Property, Plant and Equipment – Proceeds before Intended Use	香港會計準則第16號之修訂	物業、廠房及設備—作擬定用途前之所得款項
Amendments to HKAS 37	Onerous Contracts – Cost of Fulfilling a Contract	香港會計準則第37號之修訂	虧損合約—履行合約之成本
Amendments to HKFRS 3	Reference to the Conceptual Framework	香港財務報告準則第3號之修訂	對概念框架之提述
Amendments to HKFRS 16	COVID-19-Related Rent Concessions beyond 30 June 2021	香港財務報告準則第16號之修訂	於二零二一年六月三十日後之COVID-19相關租金優惠
Amendments to HKFRSs	Annual Improvements to HKFRSs 2018–2020	香港財務報告準則之修訂	香港財務報告準則二零一八年至二零二零年之年度改進

The application of these amendments to HKFRS has had no material effect on the amounts reported in these unaudited condensed consolidated financial statements and/or disclosures set out in these unaudited condensed consolidated financial statements.

2. 主要會計政策(續)

於本報告期間，本集團就編製未經審核簡明綜合財務報表首次應用香港會計師公會所頒佈於二零二二年一月一日或之後開始之年度期間強制生效之下列香港財務報告準則之修訂。香港財務報告準則包括香港財務報告準則；香港會計準則；以及香港(國際財務報告詮釋委員會)詮釋、香港詮釋及香港(準則詮釋委員會)詮釋。

香港會計準則第16號之修訂	物業、廠房及設備—作擬定用途前之所得款項
香港會計準則第37號之修訂	虧損合約—履行合約之成本
香港財務報告準則第3號之修訂	對概念框架之提述
香港財務報告準則第16號之修訂	於二零二一年六月三十日後之COVID-19相關租金優惠
香港財務報告準則之修訂	香港財務報告準則二零一八年至二零二零年之年度改進

應用該等香港財務報告準則之修訂對本未經審核簡明綜合財務報表所呈報之金額及/或本未經審核簡明綜合財務報表所載之披露事項並無重大影響。

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

The Group has not early applied the following new and amendments to HKFRS that have been issued but are not yet effective:

HKFRS 17	Insurance Contracts and the related Amendments ¹
Amendments to HKAS 1	Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 (2020) ¹
Amendments to HKAS 1 and HKFRS Practice Statement 2	Disclosure of Accounting Policies ¹
Amendments to HKAS 8	Definition of Accounting Estimates ¹
Amendments to HKAS 12	Deferred Tax related to Assets and Liabilities arising from a Single Transaction ¹
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture ²

¹ Effective for annual periods beginning on or after 1 January 2023, earlier application is permitted

² Effective date to be determined

The Group has already commenced an assessment of the impact of these new and amendments to HKFRS but is not yet in a position to state whether these new and amendments to HKFRS would have a material impact on its results of operations and financial positions.

2. 主要會計政策(續)

本集團並無提早應用下列已頒佈但尚未生效之新增香港財務報告準則及香港財務報告準則之修訂：

香港財務報告準則第17號	保險合約及相關修訂 ¹
香港會計準則第1號之修訂	流動或非流動負債之分類及香港詮釋第5號(二零二零年)之相關修訂 ¹
香港會計準則第1號及香港財務報告準則實務聲明第2號之修訂	會計政策披露 ¹
香港會計準則第8號之修訂	會計估計定義 ¹
香港會計準則第12號之修訂	與一項單一交易產生之資產及負債有關之遞延稅項 ¹
香港財務報告準則第10號及香港會計準則第28號之修訂	投資者與其聯營公司或合營企業之間之資產出售或注資 ²

¹ 於二零二三年一月一日或之後開始之年度期間生效，可提早應用

² 生效日期待定

本集團已開始評估該等新增香港財務報告準則及香港財務報告準則之修訂之影響，但尚無法說明該等新增香港財務報告準則及香港財務報告準則之修訂會否對本集團之經營業績及財務狀況造成重大影響。

3. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

The preparation of unaudited condensed consolidated financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual result may differ from these estimates.

4. FINANCIAL RISK MANAGEMENT

Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including foreign currency risk, interest rate risk and other price risk), credit risk and liquidity risk.

The unaudited condensed consolidated financial statements do not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2021.

There have been no significant changes in any risk management policies of the Group since the year end.

3. 重大會計估計及判斷

編製未經審核簡明綜合財務報表需要管理層作出會對會計政策運用以及資產負債及收支的呈報金額有影響的判斷、估計及假設。實際結果可能有異於該等估計。

4. 財務風險管理

財務風險因素

本集團的活動面對多種財務風險：市場風險(包括外幣風險、利率風險及其他價格風險)、信貸風險及流動資金風險。

未經審核簡明綜合財務報表不包括全年財務報表所規定的所有財務風險管理資料及披露事項，應與本集團截至二零二一年十二月三十一日止年度的全年綜合財務報表一併閱覽。

本集團的風險管理政策自年結日以來並無任何重大變動。

4. FINANCIAL RISK MANAGEMENT (CONTINUED)

Financial assets and liabilities measured at fair value

The following tables present the fair value of the Group's financial instruments measured at the end of the reporting period on a recurring basis, categorised into the three-level fair value hierarchy as defined in HKFRS 13 "Fair Value Measurement". The level into which a fair value measurement is classified is determined with reference to the observability and significance of the inputs used in the valuation technique as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

4. 財務風險管理(續)

按公平值計量的財務資產及負債

下表呈列於報告期末，本集團分類為按香港財務報告準則第13號「公平值計量」所界定三層公平值等級並按經常性基準計量的財務工具的公平值。將公平值計量分類的等級參照估值技術所用輸入數據的可觀察程度及重要性釐定如下：

- 第一級輸入數據乃實體於計量日可取得的相同資產或負債於活躍市場的報價(未經調整)；
- 第二級輸入數據乃就資產或負債直接或間接地可觀察的輸入數據(第一級內包括的報價除外)；及
- 第三級輸入數據乃資產或負債的不可觀察輸入數據。

4. FINANCIAL RISK MANAGEMENT (CONTINUED)

4. 財務風險管理(續)

Financial assets and liabilities measured at fair value (Continued)

按公平值計量的財務資產及負債 (續)

		Fair value at 30 June 2022 於二零二二年 六月三十日 的公平值 HK\$'000 千港元 (unaudited) (未經審核)	Fair value measurements as at 30 June 2022 categorised into 於二零二二年六月三十日的 公平值計量分類為		
			Level 1 第一級 HK\$'000 千港元 (unaudited) (未經審核)	Level 2 第二級 HK\$'000 千港元 (unaudited) (未經審核)	Level 3 第三級 HK\$'000 千港元 (unaudited) (未經審核)
Financial assets:	財務資產：				
Financial assets at fair value through profit or loss	按公平值透過損益列賬的財務資產				
- Club membership debenture	一會所會籍債券	3,768	-	3,768	-
- Convertible instruments	一可換股工具	37,677	-	2,968	34,709
- Investments in life insurance policies	一人壽保險保單投資	6,057	-	6,057	-
- Unlisted warrants	一非上市認股權證	2,288	-	2,288	-
Financial assets at fair value through other comprehensive income	按公平值透過其他全面收益列賬的財務資產				
- Listed overseas equity securities	一海外上市股本證券	21,689	21,689	-	-
- Listed equity securities	一上市股本證券	552,768	552,768	-	-
- Unlisted equity securities	一非上市股本證券	78,940	-	-	78,940
- Unlisted partnership investments	一非上市合夥投資	63,864	-	-	63,864

4. FINANCIAL RISK MANAGEMENT (CONTINUED)

4. 財務風險管理(續)

Financial assets and liabilities measured at fair value (Continued)

按公平值計量的財務資產及負債 (續)

	Fair value at 31 December 2021 於二零二一年 十二月三十一日 的公平值 HK\$'000 千港元 (audited) (經審核)	Fair value measurements as at 31 December 2021 categorised into 於二零二一年十二月三十一日的 公平值計量分類為		
		Level 1 第一級 HK\$'000 千港元 (audited) (經審核)	Level 2 第二級 HK\$'000 千港元 (audited) (經審核)	Level 3 第三級 HK\$'000 千港元 (audited) (經審核)
Financial assets:	財務資產：			
Financial assets at fair value through profit or loss	按公平值透過損益列賬的財務資產			
- Club membership debenture	— 會所會籍債券	3,768	-	3,768
- Convertible instruments	— 可換股工具	18,568	-	2,968
- Investments in life insurance policies	— 人壽保險保單投資	5,856	-	5,856
- Unlisted warrants	— 非上市認股權證	2,288	-	2,288
Financial assets at fair value through other comprehensive income	按公平值透過其他全面收益列賬的財務資產			
- Listed overseas equity securities	— 海外上市股本證券	73,610	73,610	-
- Listed equity securities	— 上市股本證券	787,695	787,695	-
- Unlisted equity securities	— 非上市股本證券	78,940	-	-
- Unlisted partnership investments	— 非上市合夥投資	66,472	-	-

4. FINANCIAL RISK MANAGEMENT (CONTINUED)

Financial assets and liabilities measured at fair value (Continued)

During the six months ended 30 June 2022, there were no significant changes in the business or economic circumstances that affect the fair value of the Group's financial assets and financial liabilities.

During the six months ended 30 June 2022, there were no transfers between levels of fair value hierarchy and no changes in valuation techniques in financial assets or financial liabilities.

5. SEGMENT INFORMATION

Information reported to the Chairman of the Company, being the chief operating decision maker, for the purpose of resource allocation and assessment of segment performance focuses on the types of good delivered. No operating segments identified by the chief operating decision maker have been aggregated in arriving at the reportable segments of the Group.

Specifically, the Group's reportable and operating segments under HKFRS 8 are as follows:

Proprietary and generic products	- Manufacturing and sales of self-development and generic pharmaceutical products
Licensed-in products	- Trading of licensed-in pharmaceutical products

4. 財務風險管理(續)

按公平值計量的財務資產及負債(續)

於截至二零二二年六月三十日止六個月，本集團並無明顯業務變化或經濟環境轉變，而會影響財務資產及財務負債的公平值。

於截至二零二二年六月三十日止六個月，財務資產及財務負債的公平值等級之間並無轉撥，估值技術亦無變動。

5. 分部資料

向本公司主席(即主要經營決策者)呈報以供分配資源及評估分部表現之資料側重於所交付貨品之類型。於達致本集團之可呈報分部時並無彙集主要經營決策者所識別之經營分部。

具體而言，根據香港財務報告準則第8號，本集團之可呈報及經營分部如下：

專利及仿製產品	- 製造及銷售自行研發及仿製之藥品
引進產品	- 買賣引進之藥品

5. SEGMENT INFORMATION (CONTINUED)

Revenue including manufacturing and trading of pharmaceutical products are recognised at point in time.

Segment revenue and results

The following is an analysis of the Group's revenue and results by reportable and operating segments:

Six months ended 30 June

5. 分部資料(續)

收益(包括製造及買賣藥品)按時間點確認。

分部收益及業績

以下為按可呈報及經營分部劃分之本集團收益及業績分析：

截至六月三十日止六個月

		Proprietary and generic products		Licensed-in products		Consolidated	
		專利及仿製產品	專利及仿製產品	引進產品	引進產品	綜合	綜合
		2022	2021	2022	2021	2022	2021
		二零二二年	二零二一年	二零二二年	二零二一年	二零二二年	二零二一年
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元	千港元	千港元
		(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)	(未經審核)	(未經審核)
Segment revenue	分部收益	252,087	249,635	397,079	334,417	649,166	584,052
Segment operating results	分部經營業績	85,948	114,202	105,795	70,236	191,743	184,438
Research and development expenses	研究及開發費用	(30,915)	(28,653)	(85,675)	(84,246)	(116,590)	(112,899)
Provision for impairment of intangible assets	無形資產減值撥備	-	(43,307)	-	(186,629)	-	(229,936)
Write-off of intangible assets	撇銷無形資產	-	(355)	-	-	-	(355)
Segment results	分部業績	55,033	41,887	20,120	(200,639)	75,153	(158,752)
Unallocated income	未分配收入					8,033	2,331,338
Unallocated expenses	未分配費用					(27,366)	(29,473)
Profit from operations	經營溢利					55,820	2,143,113
Finance costs	財務成本					(3,499)	(2,523)
Profit before share of results of associates	分佔聯營公司業績前溢利					52,321	2,140,590
Share of results of associates	分佔聯營公司業績					(526)	(3,311)
Profit before taxation	除稅前溢利					51,795	2,137,279
Taxation	稅項					(24,713)	(3,377)
Profit for the period	本期間溢利					27,082	2,133,902

5. SEGMENT INFORMATION (CONTINUED)

Segment revenue and results (Continued)

Segment revenue reported above represents revenue generated from external customers. There were no inter-segment sales in the current interim period (six months ended 30 June 2021: Nil).

Segment assets and liabilities

The following is an analysis of the Group's assets and liabilities by reportable and operating segments for the period/year:

		Proprietary and generic products 專利及仿製產品		Licensed-in products 引進產品		Consolidated 綜合	
		30 June 2022 二零二二年六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年十二月三十一日 HK\$'000 千港元 (audited) (經審核)	30 June 2022 二零二二年六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年十二月三十一日 HK\$'000 千港元 (audited) (經審核)	30 June 2022 二零二二年六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年十二月三十一日 HK\$'000 千港元 (audited) (經審核)
Segment assets	分部資產	789,093	884,279	1,377,165	1,509,248	2,166,258	2,393,527
Unallocated assets	未分配資產					1,076,912	1,243,371
Total assets	資產總值					3,243,170	3,636,898
Segment liabilities	分部負債	206,017	233,565	552,143	574,211	758,160	807,776
Unallocated liabilities	未分配負債					420,347	437,960
Total liabilities	負債總額					1,178,507	1,245,736

5. 分部資料(續)

分部收益及業績(續)

上文呈報之分部收益指來自外部客戶之收益。於本中期間內並無分部間銷售(截至二零二一年六月三十日止六個月：無)。

分部資產及負債

以下為按可呈報及經營分部劃分之本集團本期間/年度資產及負債分析：

5. SEGMENT INFORMATION (CONTINUED)

Geographical information

During the six months ended 30 June 2022 and 2021, more than 90% of the Group's revenue was derived from activities conducted in the People's Republic of China (the "PRC"), no geographical information on revenue is presented.

The following is an analysis of the Group's assets and liabilities by geographical market for the period/year:

5. 分部資料(續)

地區資料

於截至二零二二年及二零二一年六月三十日止六個月，本集團逾90%收益源自於中華人民共和國（「中國」）進行之業務，故此並無呈列收益地區資料。

以下為按地區市場劃分之本集團本期間／年度資產及負債分析：

		The PRC 中國		Hong Kong and others 香港及其他		Total 總計	
		30 June 2022 二零二二年 六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 HK\$'000 千港元 (audited) (經審核)	30 June 2022 二零二二年 六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 HK\$'000 千港元 (audited) (經審核)	30 June 2022 二零二二年 六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 HK\$'000 千港元 (audited) (經審核)
Total assets	資產總值	1,910,393	2,002,754	1,332,777	1,634,144	3,243,170	3,636,898
Total liabilities	負債總額	489,748	532,981	688,759	712,755	1,178,507	1,245,736

6. OTHER INCOME

6. 其他收入

		For the three months ended 30 June		For the six months ended 30 June	
		截至六月三十日止三個月		截至六月三十日止六個月	
		2022	2021	2022	2021
		二零二二年	二零二一年	二零二二年	二零二一年
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Interest income on:	下列各項之利息收入：				
Bank deposits	銀行存款	533	555	1,183	1,392
Financial assets at fair value through profit or loss	按公平值透過損益列賬之財務資產	-	83	-	83
Advance to associates	墊付予聯營公司之款項	-	828	-	1,579
Total interest income	利息收入總額	533	1,466	1,183	3,054
Development and government grants	開發及政府補助	2,658	5,834	17,094	10,615
Rental and utilities income	租金及公共服務收入	4,138	2,105	5,997	4,920
Research and development service income	研究及開發服務收入	12,890	23,333	19,220	45,004
Sundry income	雜項收入	862	619	2,208	1,345
		21,081	33,357	45,702	64,938

The Group received the development grants from local government as recognition of the Group's performance and development of high-technology pharmaceutical products.

本集團收到地方政府認可本集團表現及開發高新科技藥品而授予之開發補助。

7. PROFIT BEFORE TAXATION

Profit before taxation has been arrived at after charging/(crediting) the following items:

7. 除稅前溢利

除稅前溢利已扣除／(計入)下列各項：

	For the three months ended		For the six months ended		
	30 June		30 June		
	截至六月三十日止三個月		截至六月三十日止六個月		
	2022	2021	2022	2021	
	二零二二年	二零二一年	二零二二年	二零二一年	
	HK\$'000	HK\$'000	HK\$'000	HK\$'000	
	千港元	千港元	千港元	千港元	
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	
	(未經審核)	(未經審核)	(未經審核)	(未經審核)	
Depreciation of property, plant and equipment (including right-of-use assets)	物業、廠房及設備 (包括使用權資產) 折舊	28,374	29,496	60,606	58,225
Amortisation of intangible assets	無形資產攤銷	9,382	7,362	17,930	12,537
Total depreciation and amortisation	折舊及攤銷總額	37,756	36,858	78,536	70,762
Gain on deemed disposal of interest in an associate	視為出售一間聯營公司 權益之收益	-	(2,321,626)	-	(2,321,626)
Provision for impairment on intangible assets	無形資產減值撥備	-	229,936	-	229,936
Write-off of intangible assets	撇銷無形資產	-	355	-	355
Interest expenses on borrowings	借款之利息開支	1,284	827	2,513	1,722
Interest expenses on lease liabilities	租賃負債之利息開支	100	171	226	327
Share-based payments	以股份支付之款項	3,298	4,965	6,349	8,498
- Directors	—董事	2,342	3,113	4,441	5,005
- Employees	—僱員	956	1,852	1,908	3,493

8. TAXATION

8. 稅項

		For the three months ended 30 June		For the six months ended 30 June	
		截至六月三十日止三個月		截至六月三十日止六個月	
		2022	2021	2022	2021
		二零二二年	二零二一年	二零二二年	二零二一年
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Current tax	即期稅項				
Hong Kong Profits Tax	香港利得稅	5,425	7,842	12,436	15,202
PRC Enterprise Income Tax	中國企業所得稅	(1,373)	(912)	362	-
		4,052	6,930	12,798	15,202
Over provision in prior years	過往年度超額撥備				
PRC Enterprise Income Tax	中國企業所得稅	-	(530)	-	(530)
Deferred tax	遞延稅項				
Origination and reversal of temporary differences	產生及撥回暫時差額	7,815	(10,498)	11,915	(11,295)
		11,867	(4,098)	24,713	3,377

Hong Kong Profits Tax for the three and six months ended 30 June 2022 is calculated at 8.25% (three and six months ended 30 June 2021: 8.25%) on the first HK\$2 million of the estimated assessable profits and at 16.5% (three and six months ended 30 June 2021: 16.5%) on the estimated assessable profits above HK\$2 million according to the two-tiered profits tax rates regime.

Tax arising in the PRC is calculated at the tax rates prevailing in the PRC. Taxation arising in other jurisdictions is calculated at the tax rate prevailing in the relevant jurisdictions.

按照利得稅兩級制，截至二零二二年六月三十日止三個月及六個月之香港利得稅就首二百萬港元估計應課稅溢利按8.25%（截至二零二一年六月三十日止三個月及六個月：8.25%）及就二百萬港元以上估計應課稅溢利按16.5%（截至二零二一年六月三十日止三個月及六個月：16.5%）計算。

於中國產生之稅項按中國現行稅率計算。於其他司法權區產生之稅項按有關司法權區之現行稅率計算。

9. DIVIDENDS

9. 股息

	For the three months ended		For the six months ended		
	30 June		30 June		
	截至六月三十日止三個月		截至六月三十日止六個月		
	2022	2021	2022	2021	
	二零二二年	二零二一年	二零二二年	二零二一年	
	HK\$'000	HK\$'000	HK\$'000	HK\$'000	
	千港元	千港元	千港元	千港元	
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	
	(未經審核)	(未經審核)	(未經審核)	(未經審核)	
Interim dividend declared – HK\$0.010 (2021: HK\$0.030) per ordinary share based on issued share capital at the end of the reporting period	根據報告期末之已發行 股本計算，已宣派之 中期股息—每股普通 股0.010港元 (二零二一年： 0.030港元)	5,888	17,665	5,888	17,665

Interim dividend will be payable on 27 September 2022 to shareholders registered in the Company's register of members as at the close of business on 15 September 2022. This dividend was declared after the interim reporting date, and therefore has not been included as a liability in the condensed consolidated statement of financial position. 2021 final dividend of HK\$0.031 per share, totalling HK\$18,254,000 was paid on 15 June 2022.

本公司將於二零二二年九月二十七日向於二零二二年九月十五日營業時間結束時在本公司股東名冊登記之股東派付中期股息。由於此股息於中期報告日期後宣派，因此並未作為負債計入簡明綜合財務狀況表。二零二一年末期股息每股0.031港元(合計18,254,000港元)已於二零二二年六月十五日派付。

10. EARNINGS PER SHARE

10. 每股盈利

The calculation of basic and diluted earnings per share attributable to the owners of the Company is based on the following data:

本公司擁有人應佔每股基本及攤薄盈利乃基於下列數據計算：

		For the three months ended 30 June		For the six months ended 30 June	
		截至六月三十日止三個月		截至六月三十日止六個月	
		2022	2021	2022	2021
		二零二二年	二零二一年	二零二二年	二零二一年
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Earnings:	盈利：				
Net profit attributable to the owners of the Company for the purpose of basic and diluted earnings per share	就計算每股基本及攤薄盈利而言之本公司擁有人應佔純利	8,153	2,114,152	28,460	2,155,200

		For the three months ended 30 June		For the six months ended 30 June	
		截至六月三十日止三個月		截至六月三十日止六個月	
		2022	2021	2022	2021
		二零二二年	二零二一年	二零二二年	二零二一年
		Share(s)'000	Share(s)'000	Share(s)'000	Share(s)'000
		千股	千股	千股	千股
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Number of shares:	股份數目：				
Weighted average number of ordinary shares for the purpose of basic earnings per share	就計算每股基本盈利而言之普通股加權平均數	588,835	588,789	588,835	588,459
Effect of dilutive potential ordinary shares:	潛在攤薄普通股之影響：				
Options	購股權	-	237	-	394
Weighted average number of ordinary shares for the purpose of diluted earnings per share	就計算每股攤薄盈利而言之普通股加權平均數	588,835	589,026	588,835	588,853

11. PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS

(a) Right-of-use assets

During the six months ended 30 June 2022, the Group entered into a number of lease agreements and therefore recognised the additions to right-of-use assets of approximately HK\$2 million (six months ended 30 June 2021: approximately HK\$11 million).

(b) Owned property, plant and equipment

During the six months ended 30 June 2022, additions to owned property, plant and equipment amount to approximately HK\$7 million (six months ended 30 June 2021: approximately HK\$26 million).

11. 物業、廠房及設備以及無形資產

(a) 使用權資產

於截至二零二二年六月三十日止六個月，本集團訂立多項租賃協議，並因此確認新增使用權資產約2,000,000港元（截至二零二一年六月三十日止六個月：約11,000,000港元）。

(b) 自有物業、廠房及設備

於截至二零二二年六月三十日止六個月，新增自有物業、廠房及設備約7,000,000港元（截至二零二一年六月三十日止六個月：約26,000,000港元）。

11. PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS (CONTINUED)

(c) Intangible assets

During the six months ended 30 June 2022, additions to intangible assets amount to approximately HK\$90 million (six months ended 30 June 2021: approximately HK\$228 million), which consist of both license fees and development cost.

During the six months ended 30 June 2022, there is no provision for impairment on, or write-off of, intangible assets recognised in profit or loss.

During the six months ended 30 June 2021, the Group concluded that a total of 14 drug development programs in several therapeutics areas would be postponed or terminated about considering the future revenue potentials thereof which may make them become financially not viable; and 1 launched oral antihypertensive product to be impaired as a result of the recent volume-based procurement program which pose higher pressure on price setting for this product. A total of approximately HK\$230 million impairment provision for, and write-off of, intangible assets for the above mentioned programs and product were recognised in profit or loss.

11. 物業、廠房及設備以及無形資產(續)

(c) 無形資產

於截至二零二二年六月三十日止六個月，新增無形資產約90,000,000港元(截至二零二一年六月三十日止六個月：約228,000,000港元)，當中包括專利費及開發成本。

於截至二零二二年六月三十日止六個月，概無於損益內確認無形資產之減值撥備或撇銷。

於截至二零二一年六月三十日止六個月，本集團總結將會押後或終止在多個治療領域之合共14個藥物開發項目，乃基於其未來收益潛力考量而可能在財政上成為不可行；以及有1項已上市之口服抗高血壓產品因近期藥品集中帶量採購加重產品訂價壓力而出現減值。本集團已於損益內就上述項目及產品之無形資產確認合共約230,000,000港元減值撥備及撇銷。

12. INTERESTS IN ASSOCIATES

Details of the Group's interests in associates are as follows:

12. 於聯營公司之權益

本集團於聯營公司之權益詳情如下：

		30 June 2022 二零二二年 六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 HK\$'000 千港元 (audited) (經審核)
At beginning of the period/ year	於期／年初	6,267	6,056
Additions	添置	-	3,632
Share of post-acquisition loss	分佔收購後虧損	(526)	(3,495)
Share of exchange reserve	分佔匯兌儲備	-	46
Share of option reserve	分佔購股權儲備	-	28
At end of the period/year	於期／年末	5,741	6,267

12. INTERESTS IN ASSOCIATES (CONTINUED)

Details of the Group's associates at the end of the reporting period/year are as follows:

12. 於聯營公司之權益(續)

於報告期末/年末，本集團聯營公司之詳情如下：

Name of associate 聯營公司名稱	Place of incorporation/ operations 註冊成立/經營地點	Proportion of ownership interest held by the Group 本集團所持有之所有權權益比例		Proportion of voting rights held by the Group 本集團所持有之投票權比例		Principal activities 主要業務
		30 June 2022 二零二二年 六月三十日	31 December 2021 二零二一年 十二月三十一日	30 June 2022 二零二二年 六月三十日	31 December 2021 二零二一年 十二月三十一日	
Powder Pharmaceuticals Incorporated	British Virgin Islands/ Hong Kong	33.92%	33.92%	33.92%	33.92%	Development, manufacturing and sale of pharmaceutical products
普樂藥業有限公司	英屬處女群島/香港					開發、製造及銷售藥品
RIT Biotech (Holding) Company Limited ("RIT")	British Virgin Islands/ Hong Kong	24.08%*	24.08%	24.08%*	24.08%	Operating a central pharmacy for compounding radiopharmaceuticals
RIT Biotech (Holding) Company Limited ("RIT")	英屬處女群島/香港					經營複合放射性藥物之 中央藥房
ZERO Biotech Company Limited ("ZERO") 智和生物科技有限公司 ("智和")	Hong Kong/ Hong Kong 香港/香港	36.32%	36.32%	36.32%	36.32%	Investment holding 投資控股

* On 9 June 2022, ZERO and certain shareholders of RIT (including the Company) executed a share swap transaction, for which ZERO issued total 2,896 new shares in exchange for total 2,896 shares in RIT held by these RIT's shareholders (representing approximately 66.3% of the total issued shares of RIT). Upon completion, RIT became a non-wholly owned subsidiary of ZERO while the Company's interests held in RIT and ZERO has no effective changes.

* 於二零二二年六月九日，智和與RIT若干股東(包括本公司)進行股份互換交易，據此，智和發行合共2,896股新股份，以交換該等RIT股東所持2,896股RIT股份，相當於RIT已發行股份總數約66.3%。於完成後，RIT成為智和之非全資附屬公司，而本公司於RIT及智和所持權益並無實際變化。

12. INTERESTS IN ASSOCIATES (CONTINUED)

Deemed disposal of an associate

During the six months ended 30 June 2021, on 29 April 2021, Zhaoke Ophthalmology Limited ("ZKO") was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "ZKO Listing") by issuing new shares. Before the ZKO Listing, the Company, through a wholly-owned subsidiary, indirectly controlled approximately 33.58% of the total issued share capital of ZKO. Upon the completion of the ZKO listing, the Company, through a wholly-owned subsidiary, indirectly controlled approximately 25.82% of the total issued share capital of ZKO. Since the Group will not exercise significant influence over the operation of ZKO, ZKO ceased to be an associate of the Company and was accounted for as financial assets at fair value through other comprehensive income thereafter. This transaction had resulted in the Group recognising a gain of HK\$2.3 billion in profit or loss grouped under the line "other gains and losses, net", calculated as follows:

12. 於聯營公司之權益(續)

視為出售一間聯營公司

於截至二零二一年六月三十日止六個月，於二零二一年四月二十九日，兆科眼科有限公司(「兆科眼科」)藉發行新股份在香港聯合交易所有限公司主板上市(「兆科眼科上市」)。於兆科眼科上市前，本公司經由一間全資附屬公司間接控制兆科眼科已發行股本總額約33.58%。於兆科眼科上市完成後，本公司經由一間全資附屬公司間接控制兆科眼科已發行股本總額約25.82%。由於本集團對兆科眼科之營運再無重大影響力，因此兆科眼科不再為本公司之聯營公司，並於其後入賬列作按公平值透過其他全面收益列賬之財務資產。此項交易導致本集團於損益內確認歸類為「其他收益及虧損淨額」之收益23億港元，其計算方式如下：

		HK\$'000 千港元
Fair value of investment retained	已保留之投資公平值	2,321,626
Less: Carrying amount of the investment on the date of loss of significant influence of ZKO	減：於喪失對兆科眼科之重大影響力當日，投資之賬面金額	-
Gain recognised in profit or loss	於損益內確認之收益	2,321,626

13. TRADE RECEIVABLES

The Group allows an average credit period of 30–120 days to its trade customers.

The following is an analysis of trade receivables by age, presented based on the invoice date, which approximates the revenue recognition dates, and net of allowance for expected credit loss at the end of the reporting period:

13. 應收貿易賬款

本集團給予貿易客戶30至120日之平均信貸期。

以下為基於發票日期(與收益確認日期相若)所呈列應收貿易賬款於報告期末之賬齡分析，當中已扣除預期信貸虧損撥備：

		30 June 2022 二零二二年 六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 HK\$'000 千港元 (audited) (經審核)
0–30 days	0至30日	64,172	83,225
31–120 days	31至120日	76,536	79,836
121–180 days	121至180日	2,167	5,022
181–365 days	181至365日	882	225
Over 365 days and under 3 years	365日以上及三年 以內	11	15
		143,768	168,323

14. TRADE PAYABLES

The average credit period on purchases of certain goods is 90 days.

The following is an analysis of trade payables by age, presented based on invoice date, at the end of the reporting period:

14. 應付貿易賬款

購買若干貨品之平均信貸限期為90日。

以下為基於發票日期所呈列應付貿易賬款於報告期末之賬齡分析：

		30 June 2022 二零二二年 六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 HK\$'000 千港元 (audited) (經審核)
0-90 days	0至90日	65,011	56,884
91-180 days	91至180日	999	-
181-365 days	181至365日	159	5,403
Over 365 days	365日以上	522	312
		66,691	62,599

15. BANK BORROWINGS

15. 銀行借款

		30 June	31 December
		2022	2021
		二零二二年	二零二一年
		六月三十日	十二月三十一日
		HK\$'000	HK\$'000
		千港元	千港元
		(unaudited)	(audited)
		(未經審核)	(經審核)
Secured bank borrowings classified as current liabilities (Note a)	分類為流動負債之有抵押銀行借款 (附註a)	125,172	150,280
Unsecured bank borrowings classified as current liabilities	分類為流動負債之無抵押銀行借款	11,242	12,260
		136,414	162,540
Secured bank borrowings classified as non-current liabilities	分類為非流動負債之有抵押銀行借款	84,090	84,090
		220,504	246,630
Carrying amount of the bank borrowings are repayable (Note b):	銀行借款賬面金額須於下列期間償還 (附註b):		
Within one year	一年內	136,414	142,540
More than one year but not exceeding two years	超過一年但不超過兩年	6,727	26,727
More than two years but not exceeding five years	超過兩年但不超過五年	77,363	77,363
		220,504	246,630

Notes:

- a. As the bank borrowings include a clause that gives the lenders the unconditional right to call the borrowings at any time (“**Repayment on Demand Clause**”), according to Hong Kong Interpretation 5 which requires the classification of whole borrowings containing the Repayment on Demand Clause as current liabilities, the bank borrowings were classified as current liabilities.
- b. The table is based on the agreed repayment schedule provided by banks.

附註:

- a. 由於銀行借款包含賦予貸方無條件權利隨時催繳借款之條文(「**按要求還款條文**」)，故根據香港詮釋第5號(其規定將載有按要求還款條文之借款整筆分類為流動負債)，銀行借款已分類為流動負債。
- b. 該表以銀行提供之協定還款時間表為基礎。

15. BANK BORROWINGS (CONTINUED)

Bank borrowings carry floating interest rates which is adjusted with reference to Hong Kong Interbank Offered Rate, Prime Rate or Loan Prime Rate at both 30 June 2022 and 31 December 2021. As at 30 June 2022, the effective interest rates of Group's bank borrowings ranged from 1.69% to 3.85% (31 December 2021: 1.39% to 3.85%) per annum.

The Group's bank borrowings are denominated in the following currencies:

15. 銀行借款(續)

於二零二二年六月三十日及二零二一年十二月三十一日，銀行借款均按浮動利率(經參考香港銀行同業拆息、最優惠利率或貸款最優惠利率作出調整)計息。於二零二二年六月三十日，本集團銀行借款之實際年利率介乎1.69%至3.85%(二零二一年十二月三十一日：1.39%至3.85%)。

本集團銀行借款以下列貨幣計值：

		30 June 2022 二零二二年 六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 HK\$'000 千港元 (audited) (經審核)
Hong Kong Dollars	港元	186,798	209,722
United States Dollars	美元	22,464	24,648
Renminbi	人民幣	11,242	12,260
		220,504	246,630

16. SHARE CAPITAL

16. 股本

		Number of shares 股份數目		Share capital 股本	
		30 June 2022 二零二二年 六月三十日	31 December 2021 二零二一年 十二月三十一日	30 June 2022 二零二二年 六月三十日	31 December 2021 二零二一年 十二月三十一日
		(unaudited) (未經審核)	(audited) (經審核)	(unaudited) (未經審核)	(audited) (經審核)
				HK\$'000 千港元	HK\$'000 千港元
Authorised:	法定：				
Ordinary shares of HK\$0.05 each	每股面值0.05港元之 普通股	1,000,000,000	1,000,000,000	50,000	50,000
Issued and fully paid:	已發行及已繳足：				
At beginning of the period/year	於期/年初	588,835,343	588,125,343	29,442	29,406
Exercise of share options	行使購股權	-	710,000	-	36
At end of the period/year	於期/年末	588,835,343	588,835,343	29,442	29,442

17. RELATED PARTY TRANSACTIONS 17. 關聯方交易

During the reporting period, the Group entered into the following transactions with related parties. In the opinion of the directors of the Company, the following transactions arose in the ordinary course of the Group's business.

於報告期內，本集團與關聯方進行以下交易。本公司董事認為，下列交易乃於本集團日常業務中產生。

(a) Transaction with associates

(a) 與聯營公司之交易

For the six months ended 30 June

截至六月三十日止六個月

		2022	2021
		二零二二年	二零二一年
		HK\$'000	HK\$'000
		千港元	千港元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
Interest income	利息收入	-	1,579
Rental and utilities income	租金及公共服務收入	-	3,960
Research and development service income	研究及開發服務收入	-	21,780
Purchase of consumable	採購消耗品	-	2,728

17. RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Compensation of key management personnel

The remuneration of directors and other members of key management during the period were as follows:

17. 關聯方交易(續)

(b) 主要管理人員之補償

期內，董事及其他主要管理人員之薪酬如下：

		For the six months ended 30 June	
		截至六月三十日止六個月	
		2022	2021
		二零二二年	二零二一年
		HK\$'000	HK\$'000
		千港元	千港元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
Short-term employee benefits	短期僱員福利	8,541	6,629
Share-based payments	以股份支付之款項	4,441	5,005
Retirement and other post-employment benefits	退休及其他離職後福利	2,609	12,009
- Defined contribution plan	一定額供款計劃	9	9
- Retirement benefits	一退休福利	2,600	12,000
		15,591	23,643

(c) Donation to Lee's Pharmaceutical – Kanya Lee Scholarship Limited ("Kanya Lee Scholarship")

During the six months ended 30 June 2022, a total of HK\$1,900,000 (six months ended 30 June 2021: HK\$600,000) was donated to Kanya Lee Scholarship. Ms. Leelalertsuphakun Wanee and Ms. Lee Siu Fong, directors of the Company, are also members of key management of Kanya Lee Scholarship and Kanya Lee Scholarship is considered as a related party to the Group.

(c) 向李氏大藥廠 – 李杜靜芳獎學金有限公司(「李杜靜芳獎學金」)作出捐獻

於截至二零二二年六月三十日止六個月，向李杜靜芳獎學金捐獻合共1,900,000港元(截至二零二一年六月三十日止六個月：600,000港元)。本公司董事李焯妮女士及李小芳女士亦為李杜靜芳獎學金之主要管理層成員，而李杜靜芳獎學金被視為本集團之關聯方。

18. CAPITAL COMMITMENTS

18. 資本承擔

		30 June 2022 二零二二年 六月三十日 HK\$'000 千港元 (unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 HK\$'000 千港元 (audited) (經審核)
Capital commitments contracted for in respect of:	已就下列各項訂約之資本承擔：		
Financial assets at fair value through other comprehensive income	按公平值透過其他全面收益列賬之財務資產	36,730	39,119
Intangible assets – license fee and development cost	無形資產－專利費及開發成本	116,176	125,162
Property, plant and equipment	物業、廠房及設備	79,456	85,567
		232,362	249,848

19. PLEDGE OF ASSETS

At both 30 June 2022 and 31 December 2021, the Group has no pledge of assets.

19. 資產抵押

於二零二二年六月三十日及二零二一年十二月三十一日，本集團均無已抵押之資產。

20. CONTINGENT LIABILITIES

Financial guarantee to associate

As at 30 June 2022, the Group had contingent liabilities amounting to HK\$53,000,000 (31 December 2021: HK\$53,000,000) in respect of financial guarantees given to bank for the banking facilities granted to associate. A total of approximately HK\$1,809,000 (31 December 2021: approximately HK\$1,205,000) has not been utilised by the associate.

The directors of the Company have considered the probability of default is remote. Accordingly, no provision has been made in the consolidated financial statements for the guarantee.

20. 或然負債

向聯營公司提供財務擔保

於二零二二年六月三十日，本集團有53,000,000港元（二零二一年十二月三十一日：53,000,000港元）或然負債，與就一間聯營公司獲授銀行融資向銀行作出財務擔保有關。總額約1,809,000港元（二零二一年十二月三十一日：約1,205,000港元）尚未被該聯營公司動用。

本公司董事考慮到違約的可能性甚低。因此，並無於綜合財務報表內就擔保作出撥備。

